<SEC-DOCUMENT>0001493152-25-015785.txt : 20250926
<SEC-HEADER>0001493152-25-015785.hdr.sgml : 20250926
<ACCEPTANCE-DATETIME>20250926171629
ACCESSION NUMBER:		0001493152-25-015785
CONFORMED SUBMISSION TYPE:	10-K/A
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20250531
FILED AS OF DATE:		20250926
DATE AS OF CHANGE:		20250926

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOMERICA INC
		CENTRAL INDEX KEY:			0000073290
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				952645573
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0531

	FILING VALUES:
		FORM TYPE:		10-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37863
		FILM NUMBER:		251351418

	BUSINESS ADDRESS:	
		STREET 1:		17571 VON KARMAN AVENUE
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92614
		BUSINESS PHONE:		9493792875

	MAIL ADDRESS:	
		STREET 1:		17571 VON KARMAN AVENUE
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92614

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NMS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19871130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUCLEAR MEDICAL SYSTEMS INC
		DATE OF NAME CHANGE:	19830216

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUCLEAR INSTRUMENTS INC
		DATE OF NAME CHANGE:	19720508
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K/A
<SEQUENCE>1
<FILENAME>form10-ka.htm
<DESCRIPTION>10-K/A
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:BMRA="http://biomerica.com/20250531">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_031_BMRA_biomerica.com_20250531 -->
<!-- Field: Set; Name: xdx; ID: xdx_045_20240601_20250531 -->
<!-- Field: Set; Name: xdx; ID: xdx_055_edei%2D%2DAmendmentFlag_true -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_054_edei%2D%2DEntityCentralIndexKey_0000073290 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06A_Sqft_8_utr%2D%2Dsqft -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_Segment_0_Segment -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2024-06-01to2025-05-31" id="Fact000003" name="dei:AmendmentFlag">true</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-06-01to2025-05-31" id="Fact000004" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-06-01to2025-05-31" id="Fact000005" name="dei:EntityCentralIndexKey">0000073290</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="bmra-20250531.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2024-06-01to2025-05-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-01</xbrli:startDate>
        <xbrli:endDate>2025-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-09-26">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000073290</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-09-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Sqft">
      <xbrli:measure>utr:sqft</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Segment">
      <xbrli:measure>BMRA:Segment</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1pt solid; font: 1pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>WASHINGTON,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_909_edei--DocumentType_c20240601__20250531_zeXPAA4CIuck"><ix:nonNumeric contextRef="From2024-06-01to2025-05-31" id="Fact000013" name="dei:DocumentType">10-K/A</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span id="xdx_905_edei--DocumentAnnualReport_c20240601__20250531_zGjPyMTr8nJi" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2024-06-01to2025-05-31" format="ixt:booleantrue" id="Fact000014" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Annual Report Pursuant to Section 13 or 15(d) of The Securities
Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
The Fiscal Year Ended <span id="xdx_90F_edei--DocumentPeriodEndDate_c20240601__20250531_zYop8MmkmKWc"><ix:nonNumeric contextRef="From2024-06-01to2025-05-31" format="ixt:datemonthdayyearen" id="Fact000015" name="dei:DocumentPeriodEndDate"><span id="xdx_90A_edei--CurrentFiscalYearEndDate_c20240601__20250531_zis6lbTyDlnf"><ix:nonNumeric contextRef="From2024-06-01to2025-05-31" format="ixt:datemonthdayen" id="Fact000016" name="dei:CurrentFiscalYearEndDate">May 31</ix:nonNumeric></span>, <span id="xdx_906_edei--DocumentFiscalYearFocus_c20240601__20250531_zzgUfw7vahYf"><ix:nonNumeric contextRef="From2024-06-01to2025-05-31" id="Fact000017" name="dei:DocumentFiscalYearFocus">2025</ix:nonNumeric></span></ix:nonNumeric></span></b></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">or</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span id="xdx_90E_edei--DocumentTransitionReport_c20240601__20250531_z22iaHzD2iT5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2024-06-01to2025-05-31" format="ixt:booleanfalse" id="Fact000018" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transition Report Pursuant to Section 13 or 15(d) of The Securities
Exchange Act of 1934</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
The Transition Period From ______ To ______</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commission
File Number: <span id="xdx_907_edei--EntityFileNumber_c20240601__20250531_zN10CKCxNK03"><ix:nonNumeric contextRef="From2024-06-01to2025-05-31" id="Fact000019" name="dei:EntityFileNumber">001-37863</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span style="text-decoration: underline"><span id="xdx_902_edei--EntityRegistrantName_c20240601__20250531_zTrmZFZa4G"><ix:nonNumeric contextRef="From2024-06-01to2025-05-31" id="Fact000020" name="dei:EntityRegistrantName">BIOMERICA,
INC.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
Name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_908_edei--EntityIncorporationStateCountryCode_c20240601__20250531_zUBZfmpjmNBd"><ix:nonNumeric contextRef="From2024-06-01to2025-05-31" format="ixt-sec:stateprovnameen" id="Fact000021" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span id="xdx_907_edei--EntityTaxIdentificationNumber_c20240601__20250531_zbOgGr8p98s6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="From2024-06-01to2025-05-31" id="Fact000022" name="dei:EntityTaxIdentificationNumber">95-2645573</ix:nonNumeric></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
                                            or other jurisdiction of</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporation
    of organization)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
                                            Employer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    No.)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span id="xdx_903_edei--EntityAddressAddressLine1_c20240601__20250531_zBE5p5HW03Z1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="From2024-06-01to2025-05-31" id="Fact000023" name="dei:EntityAddressAddressLine1">17571
    Von Karman Avenue</ix:nonNumeric></b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, <span id="xdx_90B_edei--EntityAddressCityOrTown_c20240601__20250531_zONEObpiPr34"><ix:nonNumeric contextRef="From2024-06-01to2025-05-31" id="Fact000024" name="dei:EntityAddressCityOrTown">Irvine</ix:nonNumeric></span></span></b><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
    <span id="xdx_90B_edei--EntityAddressStateOrProvince_c20240601__20250531_zFkqh8Rvsuri"><ix:nonNumeric contextRef="From2024-06-01to2025-05-31" id="Fact000025" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric></span></span></b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><span id="xdx_902_edei--EntityAddressPostalZipCode_c20240601__20250531_zbJEyF0Ac734" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="From2024-06-01to2025-05-31" id="Fact000026" name="dei:EntityAddressPostalZipCode">92614</ix:nonNumeric></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of principal executive offices)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<span id="xdx_90F_edei--CityAreaCode_c20240601__20250531_zMBAL5TbSa3i"><b><ix:nonNumeric contextRef="From2024-06-01to2025-05-31" id="Fact000027" name="dei:CityAreaCode">949</ix:nonNumeric></b></span></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)
<span id="xdx_90F_edei--LocalPhoneNumber_c20240601__20250531_zpV10Th48bnh"><ix:nonNumeric contextRef="From2024-06-01to2025-05-31" id="Fact000028" name="dei:LocalPhoneNumber">645-2111</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered under Section 12(b) of the Exchange Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbols</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90F_edei--Security12bTitle_c20240601__20250531_z3znBRBqomC5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2024-06-01to2025-05-31" id="Fact000029" name="dei:Security12bTitle">Common
    Stock, par value $0.08</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90B_edei--TradingSymbol_c20240601__20250531_zGrnulDzfYWh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2024-06-01to2025-05-31" id="Fact000030" name="dei:TradingSymbol">BMRA</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_904_edei--SecurityExchangeName_c20240601__20250531_zr1z5EvssToh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2024-06-01to2025-05-31" format="ixt-sec:exchnameen" id="Fact000031" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span>
    <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital Market</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
&#9744; <span id="xdx_909_edei--EntityWellKnownSeasonedIssuer_c20240601__20250531_z2d9l65DJFuk"><ix:nonNumeric contextRef="From2024-06-01to2025-05-31" id="Fact000032" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
&#9744; <span id="xdx_904_edei--EntityVoluntaryFilers_c20240601__20250531_z5sNXzcBsLvd"><ix:nonNumeric contextRef="From2024-06-01to2025-05-31" id="Fact000033" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject
to such filing requirements for the past 90 days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_906_edei--EntityCurrentReportingStatus_c20240601__20250531_z66guRrF8UT3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2024-06-01to2025-05-31" id="Fact000034" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167;232.405of this chapter) during the preceding 12 months (or for such shorter period that the registrant was
required to submit such files).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_90F_edei--EntityInteractiveDataCurrent_c20240601__20250531_z3oiQMUOMSr7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2024-06-01to2025-05-31" id="Fact000035" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    Accelerated Filer &#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    Filer &#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_edei--EntityFilerCategory_c20240601__20250531_zXGzgchgTN2c" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2024-06-01to2025-05-31" format="ixt-sec:entityfilercategoryen" id="Fact000036" name="dei:EntityFilerCategory">Non-Accelerated
    Filer</ix:nonNumeric></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    Reporting Company <span id="xdx_90C_edei--EntitySmallBusiness_c20240601__20250531_zA4ZGvKubf17"><ix:nonNumeric contextRef="From2024-06-01to2025-05-31" format="ixt:booleantrue" id="Fact000037" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    Growth Company <span id="xdx_905_edei--EntityEmergingGrowthCompany_c20240601__20250531_zy0Bv3n17TV1"><ix:nonNumeric contextRef="From2024-06-01to2025-05-31" format="ixt:booleanfalse" id="Fact000038" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. <span id="xdx_903_edei--IcfrAuditorAttestationFlag_c20240601__20250531_zQ2ovXyr1003"><ix:nonNumeric contextRef="From2024-06-01to2025-05-31" format="ixt:booleanfalse" id="Fact000039" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements. <span id="xdx_90C_edei--DocumentFinStmtErrorCorrectionFlag_c20240601__20250531_zHhCgzBGP6X2"><ix:nonNumeric contextRef="From2024-06-01to2025-05-31" format="ixt:booleanfalse" id="Fact000040" name="dei:DocumentFinStmtErrorCorrectionFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Act).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
&#9744; No <span id="xdx_90D_edei--EntityShellCompany_dbF_c20240601__20250531_zWFZym9jY7Bj"><ix:nonNumeric contextRef="From2024-06-01to2025-05-31" format="ixt:booleanfalse" id="Fact000041" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate market value of the registrant&#8217;s common stock held by non-affiliates, as of November 30, 2024, was approximately
$<span id="xdx_90B_edei--EntityPublicFloat_iI_pn5n6_c20241130_zBVhWmN74R5"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2024-11-30" id="Fact000042" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.4</ix:nonFraction></span> million, based on the closing price of $3.12.
The stock price and the number of shares takes into account a 1-for-8 reverse stock split which became effective on April 21, 2025
(the &#8220;Reverse Stock Split&#8221;).</span><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
outstanding number of shares of common stock, par value $<span id="xdx_905_edei--EntityListingParValuePerShare_c20240601__20250531_zhuOF5gMNfN3"><ix:nonFraction name="dei:EntityListingParValuePerShare" contextRef="From2024-06-01to2025-05-31" id="Fact000043" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.08</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
as of September 26, 2025 was <span id="xdx_904_edei--EntityCommonStockSharesOutstanding_iI_pid_c20250926_zBb32Rz13LO5"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2025-09-26" id="Fact000044" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,869,900</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 4pt solid; font: 1pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXPLANATORY
NOTE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_980_edei--AmendmentDescription_c20240601__20250531_gBFAD-WBLLW_zQctOGpkFWca" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2024-06-01to2025-05-31" continuedAt="ConU000047-01" id="Fact000047" name="dei:AmendmentDescription">This
Amendment No. 1 on Form 10-K/A (this &#8220;Amendment No. 1&#8221;) amends the Annual Report on Form 10-K for the fiscal year ended May
31, 2025 (the &#8220;2025 Annual Report&#8221;), originally filed by Biomerica, Inc. with the Securities and Exchange Commission (the
&#8220;SEC&#8221;) on August 29, 2025. References throughout this Amendment No. 1 to &#8220;Biomerica, Inc.&#8221;, &#8220;Biomerica&#8221;,
&#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;, or the &#8220;Company&#8221; refer to Biomerica, Inc. and its subsidiaries, taken
as a whole, unless the context otherwise indicates.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_C0B_gBFAD-WBLLW_zvNQrRftuRp3"><ix:continuation continuedAt="ConU000047-02" id="ConU000047-01"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></ix:continuation></span></p>

<div id="xdx_C08_gBFAD-WBLLW_zi8UB8nvCB44"><ix:continuation id="ConU000047-02"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are filing this Amendment No. 1 pursuant to General Instruction G(3) of Form 10-K, as we do not intend to file a definitive proxy statement
for our 2025 Annual Meeting of stockholders (the &#8220;Annual Meeting&#8221;) within 120 days of the end of our fiscal year ended May
31, 2025. Accordingly, this Amendment No. 1 is being filed solely to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">amend
    and restate Part III, Items 10 (Directors, Executive Officers and Corporate Governance), 11 (Executive Compensation), 12 (Security
    Ownership of Certain Beneficial Owners and Management Related Stockholder Matters), 13 (Certain Relationships and Related Transactions,
    and Director Independence) and 14 (Principal Accountant Fees and Services) of our 2025 Annual Report, in their entirety as set forth
    herein; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">file
    new certifications of our principal executive officer and principal financial officer as exhibits to this Amendment No. 1 under Item
    15 of Part IV hereof pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
no financial statements have been included in this Amendment No. 1, and because this Amendment No. 1 does not contain or amend any disclosure
with respect to paragraphs 3, 4 and 5 of Items 307 and 308 of Regulation S-K, the corresponding certifications have been omitted. We
are not including the certifications under Section 906 of the Sarbanes-Oxley Act of 2002, as no financial statements are being filed
with this Amendment No. 1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as set forth above, no other Items of our 2025 Annual Report have been amended or revised in this Amendment No. 1, and all such other
Items shall be as set forth in such 2025 Annual Report. Accordingly, this Amendment No. 1 should be read in conjunction with the 2025
Annual Report and our other filings with the SEC. Certain capitalized terms used and not otherwise defined in this Amendment No. 1 have
the meanings given to them in the 2025 Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:continuation></div><!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Table
of Contents</b></span></p>



<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 0.65in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page
    No.</b></span></td></tr>


  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_001">PART III</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    10.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_002">DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">1</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    11.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_003">EXECUTIVE COMPENSATION</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">8</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    12.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_004">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">13</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    13.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_005">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">14</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    14.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_006">PRINCIPAL ACCOUNTING FEES AND SERVICES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">15</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_007">PART IV</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    15.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_008">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">15</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_009">SIGNATURES</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">18</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_001"></span>PART
III</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="a_002"></span>ITEM 10. DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DIRECTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the name and current age of each director nominee, the year he or she was first elected, and his or her current
position(s) with the Company. The Company does not pay a fee to any third party to identify potential nominees. The Board has not received
recommended nominees from a stockholder and none of our directors or director nominees were selected pursuant to any arrangement or understanding,
other than with our directors acting within their capacity as a director. There are no family relationships among any of our directors,
director nominees, or executive officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 24%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Age</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    Since</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Positions
    Held</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zackary
    Irani</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1997</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allen
    Barbieri</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1999</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Vice-Chairperson of the Board and Corporate Secretary</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jane
    Emerson, M.D., Ph.D.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2007</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director,
    Chairperson of Nominating &amp; Governance Committee and Member of Compensation and Audit Committees</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Catherine
    Coste</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director,
    Chairperson of Audit Committee and Member of Nominating &amp; Governance and Compensation Committees (resigned as of June 4, 2025)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eric
    Bing Chin</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director,
    Chairperson of Audit Committee and Member of Nominating &amp; Governance and Compensation Committees</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Moatazedi</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director,
    Chairperson of Compensation Committee and Member of Audit and Nominating and Governance Committees</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Background
of Nominees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Zackary
Irani</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Zackary Irani has served as a Director, Chief Executive Officer of the Company since April 1997. Until June 2024, Mr. Zackary Irani served
as the Chairperson of the Board from April 1997. Prior to that time, Mr. Zackary Irani served as the Company&#8217;s Vice-President of
Business Development. He has been an employee of the Company since 1986. During the fiscal years 2008 and 2009, Mr. Zackary Irani also
served as Chairperson of the Board of Lancer Orthodontics, Inc., a medical device company with manufacturing operations in the U.S. and
Mexico, and served as Lancer&#8217;s Chief Executive Officer from April 1997 until April 2004. Mr. Zackary Irani holds a BS degree and
an MBA degree from the University of California, Irvine - The Paul Merage School of Business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe Mr. Zackary Irani is qualified to serve on our Board because of his service as the Chief Executive Officer of the Company, his
extensive knowledge of the Company&#8217;s business and operations, his financial expertise, his education, and his knowledge of the
business sector in which the company competes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Allen
Barbieri</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Allen Barbieri served as an Executive Director and as Vice Chairperson and Corporate Secretary of the Company since August 2020. Since
January 2022, Mr. Barbieri has also concurrently served as the Chief Executive Officer of K&#252;leon LLC, a small private biotech company
engaged in development of therapeutic drugs targeting neurologic disorders. From October 1999 through August 2020, Mr. Allen Barbieri
also served as an outside independent director of the Company From March 2015 to April 2022, Mr. Allen Barbieri served as a member of
the board of directors of CareTrust REIT, Inc. (NYSE:CTRE), a large publicly traded real estate investment trust, where he served as
Chairman of the Corporate Governance and Nominating Committee and as a member of the Audit and Compensation Committees. From January
2010 to March 2018, Mr. Allen Barbieri served as the Chief Executive Officer of Biosynthetic Technologies, a privately held, renewable
specialty chemicals company, with BP and Monsanto as primary owners. Prior to that, from April 2004 to September 2009, Mr. Allen Barbieri
served as the Chief Executive Officer of Lancer Orthodontics, Inc., a medical device company with manufacturing operations in the U.S.
and Mexico. From 1998 to 1999, he served as President and Chief Financial Officer of BUY.COM, a major internet retailer, and from 1994
to 1999 Mr. Allen Barbieri was President and Chief Executive Officer of Pacific National Bank. Mr. Allen Barbieri holds an MBA from Massachusetts
Institute of Technology (MIT).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe Mr. Allen Barbieri is qualified to serve on our Board due to his extensive knowledge of the Company&#8217;s business and operations,
his financial expertise in investment banking and experience as a Chief Executive Officer and Chief Financial Officer of public and private
institutions, his education, and his prior experience as a board member of numerous public and private companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Dr.
Jane Emerson</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Jane Emerson has served as a Director of the Company since April 2007. Since July 1, 2009, Dr. Emerson has served as Vice Chair for Clinical
Programs and Chief of Clinical Pathology at the University of Southern California Keck School of Medicine, Los Angeles, California. From
1994 to 2009, Dr. Emerson was on the faculty of the University of California, Irvine School of Medicines where she served as Chief of
Clinical Pathology, and from 2000 to 2009, she served as the Vice Chair for Clinical Programs, Department of Pathology, and Laboratory
Medicine. Dr. Emerson holds a MD from the University of Virginia, completed a residency in Laboratory Medicine at Johns Hopkins, and
earned a PhD in Physics from Brown.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe Dr. Emerson is qualified to serve on our Board due to her extensive education, her industry leading experience in the clinical
laboratory sector, her knowledge of clinical lab products and the process of attaining regulatory clearance for new lab-based diagnostic
tests, and her 13 years of experience of service on the Board of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Catherine
Coste</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms.
Catherine Coste served as a Director of the Company from September 2020 to June 2025. Ms. Catherine Coste retired from Deloitte and Touche
LLP (&#8220;Deloitte&#8221;), an industry-leading audit, consulting, tax and advisory firm, in 2020, where she was a senior Partner and
served as one of Deloitte&#8217;s Life Sciences industry executive leaders. During her career at Deloitte, Ms. Catherine Coste was directly
involved with over 30 life science corporations, the majority of which were large-cap and medium-cap public corporations. Ms. Catherine
Coste has served as an Independent Director at Minerva Surgical, Inc., a commercial-stage medical technology company, since February
2021, where she is Chair of the Audit Committee and a Member of the Compensation Committee. Ms. Catherine Coste has also served as an
Independent Director at Renalytix, plc(NASDAQ: RNLX), an artificial intelligence-enable in vitro diagnostics company, since June 2023,
where she Chairs the Audit Committee and is also a Member of the Renumeration Committee. Ms. Catherine Coste spent 32 years in both corporate
and professional services positions leading global finance, internal audit and operations teams. She has extensive experience in Sarbanes-Oxley
compliance, corporate risk analysis and management, cyber risk assessment, fraud prevention, IT systems analysis and upgrades, internal
controls, and corporate governance. Ms. Catherine Coste is a Certified Public Accountant in California and holds a Bachelor of Science
in Business Administration with a focus on Accounting from California State University, Hayward.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe Ms. Catherine Coste was qualified to serve on our Board due to her education, her extensive work experience as a partner at Deloitte,
more than 20 years of experience advising life sciences companies in multiple areas of their operations including accounting and finance,
and other experience serving on the board of a public life science company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Eric
Bing Chin, CPA</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Eric Bing Chin, CPA has served as a Director of the Company since June 2025. Mr. Chin has served as the Chief Financial Officer of Akido
Labs, Inc. since January 2023 and as a board member, Treasurer, and Secretary of Rhode Island Primary Care Physicians Corporation since
December 2023. From 2018 to 2022, Mr. Chin served as Chief Financial Officer at Astrana Health, a publicly traded company and member
of the S&amp;P SmallCap 600. From 2011 to 2018, Mr. Chin served in finance leadership positions within Public Storage and Alexandria
Real Estate Equities, both of which are publicly traded and members of the S&amp;P 500. From 2002 to 2011, Mr. Chin was a practicing
CPA with EY, a global public accounting firm. Mr. Chin holds a BA degree from UCLA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Chin serves as an advisory board member for AI 2030, a fundraiser for the American Heart Association&#8217;s Executives with Heart, and
a fundraiser for the Covenant House of Los Angeles. He also actively volunteers as a mentor for the UCLA Alumni mentoring program. Mr.
Chin is also a Member of the Healthcare Financial Management Association, a Charter Member of The F-Suite, and a member of the National
Association of Corporate Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe Mr. Chin is qualified to serve on our Board due to his education, his financial expertise, his experience as a Chief Financial
Officer of healthcare companies, his professional experience, and his prior experience serving as a member of the board of directors
of a healthcare company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">David
Moatazedi</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
David Moatazedi has served as a Director of the Company since September 2020. Mr. David Moatazedi has served as the President and Chief
Executive Officer, and as a member of the of board of directors of Evolus, Inc. (&#8220;Evolus&#8221;) (NASDAQ: EOLS), since May 2018.
Evolus is a publicly traded life sciences company headquartered in Orange County, California, with a market capitalization of approximate
$500 million. From March 2017 to June 2020, David also served as an independent board member of Obalon Therapeutics, a publicly traded
life sciences company that was later merged into ReShape Lifesciences Inc. From 2016 to 2018, Mr. David Moatazedi served as Senior Vice
President at Allergan Inc. (&#8220;Allergan&#8221;), and head of the U.S. Medical Aesthetics division. Mr. David Moatazedi also worked
in various other leadership positions within Allergan since 2005, including Vice President, Sales and Marketing of the U.S. Facial Aesthetics,
and the U.S. Plastic Surgery Divisions. Before Allergan, from 2000 to 2005 Mr. David Moatazedi was a district manager for Novartis Pharmaceuticals,
a multinational pharmaceuticals company. Mr. David Moatazedi holds, an MBA from Pepperdine University and a BA degree from California
State University, Long Beach.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe Mr. David Moatazedi is qualified to serve on our Board due to his education, his financial expertise, his experience as a Chief
Executive Officer of a publicly traded life sciences company, his professional experiences, and his prior experience serving as a member
of the board of directors of a public life science company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXECUTIVE
OFFICERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the names, ages and positions of our executive officers:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 22%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Age</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 66%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Position(s)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zackary
    Irani</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allen
    Barbieri</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Vice Chairperson</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary
    Lu</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following provides certain biographical information with respective to each of our executive officers who is not a director.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zackary
    Irani</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 85%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Zackary Irani&#8217;s background is discussed above under the heading &#8220;Background of Nominees.&#8221; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allen
    Barbieri</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Allen Barbieri&#8217;s background is discussed above under the heading &#8220;Background of Nominees.&#8221; </span></td></tr>
</table>

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="text-align: center; margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 15%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary
    Lu</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 85%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Gary Lu has served as the Chief Financial Officer of the Company since March 2023. Mr. Gary Lu brings over 20 years of diverse extensive
    experience with SEC publicly traded and privately held companies in corporate strategy, financial management, operations, fundraising,
    and merger and acquisition activities. Prior to joining the Company, from September 2019 to February 2023, Mr. Gary Lu served as
    the Controller and Vice President of Finance at Happy Money, a leading platform for unsecured lending. From January 2019 to September
    2019, Mr. Gary Lu served as Controller and Vice President of Finance at Verb Technology Company, Inc. (NASDAQ: VERB), a software
    company. From January 2015 to January 2019, Mr. Gary Lu served as Vice President Southwest Corporate Controller at FirstService Residential
    Management, Inc., a property management company, and the largest subsidiary of FirstService Corporation (NASDAQ: FSV). From October
    2014 to January 2015, he served as the Corporate Controller and Head of Finance at Hoag Orthopedic Institute, LLC, a nationally ranked
    organization for orthopedic care. From December 2008 to October 2014, he served within various finance cross-disciplined roles at
    Broadcom Inc. (NASDAQ: AVGO), a semi-conductor manufacturing company. Mr. Gary Lu began his career at Ernst &amp; Young, LLP, a professional
    services company, where he served as an Assurance Manager from September 2003 to November 2008, and provided assurance services to
    both publicly traded and private company clients of the firm. Mr. Gary Lu is a certified public accountant and received a BA in Economics
    and Accounting from the University of California, Los Angeles (UCLA).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BOARD
DIVERSITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
diversity of the Company&#8217;s Board is listed below and is reviewed annually by the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="17" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Board Diversity Matrix (as of September 30, 2025)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">Total Number of Directors</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">5</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Female</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Male</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Non- Binary</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Did Not Disclose Gender</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Part I: Gender Identity</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; width: 44%">Directors</td><td style="text-align: center; width: 2%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 10%; text-align: center">1</td><td style="width: 1%; text-align: center">&#160;</td><td style="text-align: center; width: 2%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 10%; text-align: center">4</td><td style="width: 1%; text-align: center">&#160;</td><td style="text-align: center; width: 2%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 10%; text-align: center">-</td><td style="width: 1%; text-align: center">&#160;</td><td style="text-align: center; width: 2%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 10%; text-align: center">-</td><td style="width: 1%; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Part II: Demographic Background</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">African American or Black</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">-</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">-</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">-</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">-</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Alaskan Native or Native American</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">-</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">-</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">-</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">-</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Asian</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">-</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">1</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">-</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">-</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Hispanic or Latinx</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">-</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">-</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">-</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">-</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Native Hawaiian or Pacific Islander</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">-</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">-</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">-</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">-</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">White</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">1</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">3</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">-</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">-</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Two or More Races or Ethnicities</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">-</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">-</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">-</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">-</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">LGBTQ+</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">-</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">-</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">-</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">-</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Did Not Disclose Demographic Background</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">-</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">-</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">-</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">-</td><td style="text-align: center">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LEGAL
PROCEEDINGS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no legal proceedings related to any of our directors, director nominees, or executive officers which are required to be disclosed
pursuant to applicable SEC rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BOARD
OF DIRECTORS MEETINGS AND COMMITTEES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board maintains an Audit Committee, a Compensation Committee, and a Nominating and Corporate Governance Committee. For the fiscal year
ended May 31, 2025, the Board held eight in-person or telephonic Board meetings, three of which were strategy and update meetings with
management, and acted by unanimous written consent three times. The Audit Committee held seven meetings; the Compensation Committee held
four meetings; and the Nominating and Corporate Governance Committee held four meetings. During the fiscal year ended May 31, 2025, all
directors attended 75% or more of the aggregate meetings of the Board and the Committees on which they served.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOMINATING
AND CORPORATE GOVERNANCE COMMITTEE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a Nominating and Corporate Governance Committee Charter which may be viewed on the Company&#8217;s website at <span style="text-decoration: underline">www.biomerica.com</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a standing Nominating and Corporate Governance Committee (the &#8220;Governance Committee&#8221;). The Governance Committee
regularly assesses the appropriate size of the Board and whether any vacancies on the Board are expected due to retirement or otherwise
arise. In the event that vacancies are anticipated or otherwise arise, the Governance Committee utilizes a variety of methods for identifying
and evaluating director candidates. The Governance Committee will consider candidates recommended by current directors, professional
search firms, stockholders or other persons.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
select a director candidate, the Governance Committee undergoes a series of discussions and review of the candidates. Once the Governance
Committee has identified a prospective nominee, the Governance Committee will evaluate the prospective nominee in the context of the
then current composition of the Board and will consider a variety of other factors, including the prospective nominee&#8217;s public
company experience, corporate governance experience, business, technology, strategy, and industry experience, finance and financial reporting
experience, and other attributes that would be expected to contribute to an effective Board. The Board seeks to identify nominees who
possess a diverse range of experience, skills, areas of expertise, industry knowledge, business judgment, and professional ethics and
values. Although the Governance Committee does not have a formal policy with respect to diversity, it has a well-established process
to identify director nominees, and considers diversity when evaluating candidates for director nominees. The Board does not evaluate
stockholder nominees differently than any other nominee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board will consider stockholder nominations for directors if we receive timely written notice, in proper form, of the nomination. To
be timely, the notice must be received within the time frame discussed below in this Proxy Statement under the heading &#8220;Date of
Submission of Stockholder Proposals.&#8221; To be in proper form, the notice must, among other matters, include each nominee&#8217;s
written consent to serve as a director for the Company if elected at the next annual meeting, a description of all arrangements or understandings
between the nominating stockholder and the nominee, and certain other information about the nominating stockholder and the nominee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Governance Committee met four times during the fiscal year ended May 31, 2025. For the fiscal year ended May 31, 2025, the Committee
consisted of Dr. Jane Emerson, Mr. David Moatazedi and Ms. Catherine Coste with Dr. Jane Emerson serving as Chairperson of the Governance
Committee. Following our fiscal year end, on June 4, 2025, Ms. Catherine Coste resigned as an independent member of the Board, thereby
vacating her position as a member of the Governance Committee. On the same date, the Board appointed Mr. Eric Bing Chin to serve as an
independent member of the Board and also as a member of the Governance Committee filling the vacancy created by Ms. Coste&#8217;s resignation
. After the Annual Meeting, it is anticipated that Dr. Jane Emerson will continue to serve as Chair of the Governance Committee and Mr.
David Moatazedi and Mr. Eric Bing Chin will remain members.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>COMPENSATION
COMMITTEE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a Compensation Committee Charter which may be viewed on the Company&#8217;s website at <span style="text-decoration: underline">www.biomerica.com</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Committee is responsible for assisting the Board in discharging its responsibilities regarding the compensation of our employees
and directors. The specific duties of the Compensation Committee include, among other matters: reviewing and approving executive compensation;
evaluating our executive officers&#8217; performance; setting the compensation levels of our executive officers; setting our incentive
compensation plans, including our equity-based incentive plans; making recommendations to the Board for annual compensation of directors;
and making recommendations to our Board regarding our overall compensation structure, policies and programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Committee may delegate authority to the chief executive officer or the chief financial officer to grant equity incentive
plan awards to our non-executive employees consistent with the parameters approved in advance by the compensation committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically,
our Chief Executive Officer and Executive Vice-chairperson have provided input and recommendations to the Compensation Committee on the
compensation of executive officers and members of the Board. In addition, representatives from our executive management team finance
function have provided information or recommendations to the Compensation Committee regarding design of any cash and equity incentive
programs. Also, while the Compensation Committee does not officially retain an executive compensation consultant, it does obtain industry
and peer-group compensation information from certain national compensation consulting firms and other industry resources. The Compensation
Committee reviews all of this input and information in determining and setting director and executive officer compensation plans. All
decisions affecting executive officer compensation are made by the Compensation Committee, in its sole discretion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Committee met four times during the fiscal year ended May 31, 2025. One Compensation Committee meeting was held without
management, and three Compensation Committee meetings were held with management attending at least a portion of the meeting. For the
fiscal year-end May 31, 2025, the Compensation Committee was comprised of Mr. David Moatazedi, Dr. Jane Emerson and Ms. Catherine Coste,
with Mr. David Moatazedi serving as Chairperson of the Compensation Committee. Following our fiscal year end, on June 4, 2025, Ms. Catherine
Coste resigned as an independent member of the Board, thereby vacating her position as a member of the Compensation Committee. On the
same date, the Board appointed Mr. Eric Bing Chin to serve as an independent member of the Board and also as a member of the Compensation
Committee filling the vacancy created by Ms. Coste&#8217;s resignation. It is anticipated that Mr. David Moatazedi will continue to serve
as Chairperson of the Compensation Committee after the Annual Meeting, and Dr. Jane Emerson and Mr. Eric Bing Chin will remain members.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>AUDIT
COMMITTEE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has an Audit Committee Charter which may be viewed on the Company&#8217;s website at <span style="text-decoration: underline">www.biomerica.com</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee is responsible for overseeing our accounting and financial reporting processes and the audits of our financial statements.
In addition, the Audit Committee assists the Board in its oversight of our compliance with legal and regulatory requirements. The specific
duties of the Audit Committee include, among others: monitoring the integrity of our financial process and systems of internal controls
regarding finance, accounting and legal compliance; selecting our independent auditor; monitoring the independence and performance of
our independent auditor; and providing an avenue of communication among the independent auditor, our management and our Board. The Audit
Committee has the authority to conduct any investigation appropriate to fulfilling its responsibilities, and it has direct access to
all of our employees and to the independent auditor. The Audit Committee also has the ability to retain, at the Company&#8217;s expense
and without further approval of the Board, special legal, accounting, or other consultants or experts that it deems necessary in the
performance of its duties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee met four times during the fiscal year ended May 31, 2025. For the fiscal year ended May 31, 2025, the Audit Committee
consisted of Ms. Catherine Coste, Mr. David Moatazedi, and Dr. Jane Emerson with Ms. Catherine Coste serving as Chairperson of the Audit
Committee. Following our fiscal year end, on June 4, 2025, Ms. Catherine Coste resigned as an independent member of the Board, thereby
vacating her position as Chairperson of the Audit Committee. On the same date, the Board appointed Mr. Eric Bing Chin to serve as an
independent member of the Board and also as the Chairperson of the Audit Committee filling the vacancy created by Ms. Coste&#8217;s resignation.
It is anticipated that Mr. Eric Bing Chin will serve as the Chairperson of the Audit Committee after the Annual Meeting, and Dr. Jane
Emerson and Mr. David Moatazedi will remain members. The Board has determined that Mr. Eric Bing Chin qualifies as an &#8220;audit committee
financial expert&#8221; and that each member of the Audit Committee is financially literate. All members of the Audit Committee meet
the independence standards set forth in applicable Securities and Exchange Commission (&#8220;SEC&#8221;) and Nasdaq rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DIRECTOR
INDEPENDENCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board reviews the independence of each director when he or she is elected to the Board and monitors their independence on a continual
basis. The Board considers the transactions and relationships between each member and the Company in determining independence. The Board
determines independence based on the definition of &#8220;Director Independence&#8221; as defined by SEC rules and as determined in accordance
with Rule 5605 of the Marketplace Rules of Nasdaq. Based upon that review, the Board has affirmatively determined that Mr. Eric Bing
Chin, Mr. David Moatazedi, and Dr. Jane Emerson are independent, (collectively, the &#8220;Independent Directors&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BOARD
LEADERSHIP STRUCTURE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board selects a Chairperson in a manner it determines to be in the best interests of the Company. It is in the Board&#8217;s discretion
to determine whether the same individual should serve as both the Chief Executive Officer and Chairperson of the Board or whether those
roles should be separated. This flexibility permits the Board to organize its functions and conduct its business in a manner it deems
most effective in then-prevailing circumstances and to select the individual it considers to be best-suited to serve as Chairman of the
Board at any particular time. At this time, the Board has not yet appointed a new person to serve as the Chairperson of the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BOARD
ROLE IN RISK OVERSIGHT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board is responsible for oversight of material risks facing the Company, including financial, cybersecurity, and compliance risks, while
our management team is responsible for the day-to-day management of risk. In addition, the Board has delegated oversight of certain categories
of risk to the Audit Committee and the Compensation Committee, which are comprised entirely of independent directors. The Audit Committee
and the Compensation Committee respectively report to the Board as appropriate on matters that involve specific areas of risk that each
committee oversees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Financial,
Compliance and Controls Risks</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee has scheduled periodic and annual reviews and discussions with management regarding significant risk exposures and incident
metrics, including those relating to global financial, accounting, and treasury matters, internal audit and controls, and legal and regulatory
compliance. These discussions cover the steps management has taken to monitor, control, and report such exposures, as well as the Company&#8217;s
policies with respect to risk assessment and risk management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employee
Compensation Risks</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Committee oversees management of risks relating to the Company&#8217;s compensation plans and programs. The Company&#8217;s
management and the Compensation Committee have assessed the risks associated with the Company&#8217;s compensation policies and practices
for all employees, including non-executive officers. These include risks relating to setting ambitious targets for our employees&#8217;
compensation or the vesting of their equity awards, our emphasis on at-risk equity-based compensation, discrepancies in the values of
equity-based compensation depending on employee tenure relative to increases in stock price over time and the potential impact of such
factors on the retention or decision-making of our employees, particularly our senior management. Based on the results of this assessment,
the Company does not believe that its compensation policies and practices for all employees, including non-executive officers, create
risks that are reasonably likely to have a material adverse effect on the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CORPORATE
GOVERNANCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Corporate Governance Policy and its Policy on Business Conduct and Ethics (&#8220;Ethics Policy&#8221;) for all directors,
officers, and employees of the Company, including executive officers, are available on the Company&#8217;s web site at <i>www.biomerica.com</i>.
Stockholders may also obtain free of charge printed copies of this policy by writing to the Corporate Secretary of the Company at our
principal executive offices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DELINQUENT
SECTION 16(a) REPORTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
16(a) of the Exchange Act requires our executive officers, directors, and persons who own more than 10% of a registered class of securities
to file initial reports of ownership of our stock and reports of changes in such ownership with the SEC. To our knowledge, all required
filings pursuant to Section 16(a) were timely made during the fiscal year ended May 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EMPLOYEE,
DIRECTOR, AND OFFICER HEDGING</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not adopted any policy regarding the ability of our employees (including officers) or directors, or any of their designees, to purchase
financial instruments (including prepaid variable forward contracts, equity swaps, collars, and exchange funds), or otherwise engage
in transactions, that hedge or offset, or are designed to hedge or offset, any decrease in the market value of our equity securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INSIDER
TRADING POLICY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We also maintain a Policy on Insider Trading governing the purchase or sale of our securities by our officers, directors
and employees and consultants, that we believe is reasonably designed to promote compliance with insider trading laws, rules and regulations,
and any listing standards applicable to us. We consider it improper and inappropriate for any employee, officer or director to engage
in short-term or speculative transactions in our securities. The Policy on Insider Trading specifically prohibits officers, directors
and other employees and consultants from engaging in short sales, margin accounts, pledging or hedging transactions of our securities.
A copy of the Policy on Insider Trading Policy was filed as Exhibit 19.1 to our 2025 Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>COMPENSATION
RECOVERY POLICY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We believe that it is in the best interests of the Company and its stockholders to create and maintain a culture
that emphasizes integrity and accountability and reinforces our pay-for-performance compensation philosophy. We have adopted a compensation
recovery policy, which has been filed as an exhibit to our 2025 Annual Report. The compensation recovery policy provides for the recoupment
of certain executive compensation in the event of an accounting restatement resulting from material noncompliance with financial reporting
requirements under the federal securities laws and describes certain remedies available to the Board to address executive officers who
have engaged in fraudulent or other intentional misconduct. Our compensation recovery policy applies to any compensation paid to executive
officers that is granted, earned, or vested based wholly or in part upon attainment of a financial reporting measure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_003"></span>ITEM
11. EXECUTIVE COMPENSATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXECUTIVE
COMPENSATION OF NAMED EXECUTIVE OFFICERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2024, our Compensation Committee conducted its annual review of our compensation philosophy and made recommendations to the
Board, which set the total compensation plan for our Named Executive Officers. This review included certain market data, other factors,
and operational performance of the Company. The focus of the Compensation Committee, the Board, and management is aligning management
total compensation with shareholder return. As such, the Company pays below market salaries and cash bonuses (when paid) and focuses
on equity awards for Named Executive Officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
use salary to compensate our Named Executive Officers for services rendered during the year and to recognize each of their experience,
skills, knowledge, and responsibilities required of each Named Executive Officers. Our Compensation Committee considers adjustments to
salary to reflect market conditions and Company results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity
Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
view equity awards as the critical element of total compensation of our Named Executive Officers. Although we do not specifically tie
any portion of a Named Executive Officer&#8217;s equity compensation to Company performance, the Company utilizes incentive stock options
and restricted stock as equity awards, the value of which bears a direct correlation to
total shareholder return. Stock options issued to Named Executive Officers, often vest over a four-year period. Stock options issued to
Named Executive Officers are always issued with an exercise price equal to the then current market price of the Company&#8217;s Common
Stock. As such, the value in these issued stock options is tied to long-term increases in stockholder value. Further, since issued stock
options generally vest over four (4) years, these equity awards serve as a means of retaining our Named Executive Officers, as well as
other employees of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Committee and, if applicable, the Board typically grant equity awards, including, if any, stock options, during their regularly
scheduled meetings early in the fiscal year. However, the timing of this approval may be changed in the event of extraordinary circumstances,
including in connection with mid-year promotions and new hires. The Compensation Committee and the Board do not take material nonpublic
information into account when determining the timing and terms of equity awards, including options. The Compensation Committee and the
Board do not time the release of material nonpublic information to affect the value of executive compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the total compensation earned by the Company&#8217;s Chief Executive Officer, Executive Vice Chairperson and
Chief Financial Officer and Secretary (the &#8220;Named Executive Officers&#8221;) for the fiscal years ended May 31, 2025 and 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXECUTIVE
COMPENSATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUMMARY
COMPENSATION TABLE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Name and Principal Position</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Salary ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock Awards ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Option Awards ($) (4)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; text-align: center">Zackary Irani (1),</td><td style="width: 2%">&#160;</td>
    <td style="width: 11%; text-align: center">2025</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">122,596</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">78,438</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">201,034</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Chairman &amp; Chief Executive Officer</td><td>&#160;</td>
    <td style="text-align: center">2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">150,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">210,103</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">360,103</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">Allen Barbieri (2),</td><td>&#160;</td>
    <td style="text-align: center">2025</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">93,415</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,513</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">127,928</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">Director, Executive Vice Chairman &amp; Secretary</td><td>&#160;</td>
    <td style="text-align: center">2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">124,583</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">119,400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">243,983</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Gary Lu (3),</td><td>&#160;</td>
    <td style="text-align: center">2025</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">260,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51,769</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">311,769</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Chief Financial Officer</td><td>&#160;</td>
    <td style="text-align: center">2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">260,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">125,636</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">385,636</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    part of cost reduction measures during the fiscal year ended May 31, 2025,
Mr. Zackary Irani voluntarily reduced his salary from $150,000 to $75,000 effective August 1, 2024. Effective January 1, 2025, Mr. Irani&#8217;s
annual base salary was reinstated to $150,000. In the fiscal years ended May 31, 2025 and 2024, there were no management incentive cash
bonuses and Mr. Zackary Irani received no issuance of stock. Mr. Zackary Irani was granted 31,250 shares of restricted stock during the
fiscal year ended May 31, 2025. The aggregate grant-date fair value of these shares of restricted stock was $78,438, based on the closing
market price of the Company&#8217;s common stock of $2.51 per share on the date of grant.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    part of cost reduction measures during the fiscal year ended May 31, 2025,
Mr. Allen Barbieri voluntarily reduced his salary from $110,000 to $88,000 effective August 1, 2024. In the previous fiscal year ended
May 31, 2024, Mr. Allen Barbieri&#8217;s salary was voluntarily reduced from $110,000 to $88,000, effective January 1, 2024. In the fiscal
years ended May 31, 2025 and 2024, there were no management incentive cash bonuses and Mr. Allen Barbieri received no issuance of stock.
Mr. Allen Barbieri was granted 13,750 shares of restricted stock during the fiscal year ended May 31, 2025. The aggregate grant-date fair
value of these shares of restricted stock was $34,513, based on the closing market price of the Company&#8217;s common stock of $2.51
per share on the date of grant.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
    the fiscal year ended May 31, 2025, Mr. Gary Lu did not receive a salary
increase. In the previous fiscal year ended May 31, 2024, his salary became effective upon his appointment as chief financial officer
on March 1, 2023. In the fiscal years ended May 31, 2025 and 2024, there were no management incentive cash bonuses and Mr. Gary Lu received
no issuance of stock. Mr. Gary Lu was granted 20,625 shares of restricted stock during the fiscal year ended May 31, 2025. The aggregate
grant-date fair value of these shares of restricted stock was $51,769, based on the closing market price of the Company&#8217;s common
stock of $2.51 per share on the date of grant.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    additional information as to the assumptions made in valuation, see Note 2 to the Company&#8217;s audited financial statements filed
    with the SEC in our Annual Report.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employment
Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a written employment agreement with Gary Lu for his role as the Chief Financial Officer of the Company (the &#8220;Lu Employment
Agreement&#8221;). Mr. Lu&#8217;s employment is at-will and may be terminated by him or the Company at any time, with or without cause
or notice. Pursuant to the Lu Employment Agreement, Mr. Lu is entitled to separation pay under the following circumstances:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Termination
    by the Company for Cause</i>: If the Company terminates Mr. Lu for Cause (as defined in the Lu Employment Agreement), Mr. Lu is entitled
    to all accrued but unpaid base salary and any accrued but unused paid time-off to the date of the termination. </span></td></tr>
</table>

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="text-align: center; margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Termination
    by the Company without Cause</i>: If the Company terminates Mr. Lu without Cause (as defined in the Lu Employment Agreement), Mr.
    Lu shall be paid all accrued but unpaid base salary and any accrued but unused paid time-off to the date of the termination. In the
    event Mr. Lu is terminated by the Company without Cause, including following a Change in Control (as defined by the Lu Employment
    Agreement), he will be eligible for severance pay that is equal to 12 months of Mr. Lu&#8217;s base bay, provided that he executes
    and does not revoke a customary general release of claims against the Company and its affiliates, officers, directors, agents, and
    employees (the &#8220;Severance Payment&#8221;). </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Termination
    by the Employee with Cause: </i>If Mr. Lu terminates his employment with the Company with Cause, including a termination with Cause
    following a Change in Control, he will be eligible for a Severance Payment. In the event of a termination of employment by Mr. Lu
    with Cause following a Change in Control, all unvested stock options previously issued to him shall become immediately vested and
    exercisable. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a written employment agreement with Zack Irani for his role as the Chief Executive Officer of the Company (the &#8220;Irani
Employment Agreement&#8221;). Mr. Irani&#8217;s employment is at-will and may be terminated by him or the Company at any time, with or
without cause or notice. Pursuant to the Irani Employment Agreement, Mr. Irani is entitled to separation pay under the following circumstances:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Termination
    by the Company for Cause</i>: If the Company terminates Mr. Irani for Cause (as defined in the Irani Employment Agreement), Mr. Irani
    is entitled to all accrued but unpaid base salary and any accrued but unused paid time-off to the date of the termination. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Termination
    by the Company without Cause</i>: If the Company terminates Mr. Irani without Cause (as defined in the Irani Employment Agreement),
    Mr. Irani shall be paid all accrued but unpaid base salary and any accrued but unused paid time-off to the date of the termination.
    In the event Mr. Irani is terminated by the Company without Cause, including following a Change in Control (as defined by the Irani
    Employment Agreement), he will be eligible for severance pay that is equal to 12 months of Mr. Irani&#8217;s base bay, provided that
    he executes and does not revoke a customary general release of claims against the Company and its affiliates, officers, directors,
    agents, and employees (the &#8220;Severance Payment&#8221;). </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Termination
    by the Employee with Cause: </i>If Mr. Irani terminates his employment with the Company with Cause, including a termination with
    Cause following a Change in Control, he will be eligible for a Severance Payment. In the event of a termination of employment by
    Mr. Irani with Cause following a Change in Control, all unvested stock options previously issued to him shall become immediately
    vested and exercisable. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a written employment agreement with Allen Barbieri for his role as the Corporate Secretary and Executive Vice Chairman of
the Company (the &#8220;Barbieri Employment Agreement&#8221;). Mr. Barbieri&#8217;s employment is at-will and may be terminated by him
or the Company at any time, with or without cause or notice. Pursuant to the Barbieri Employment Agreement, Mr. Barbieri is entitled
to separation pay under the following circumstances:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Termination
    by the Company for Cause</i>: If the Company terminates Mr. Barbieri for Cause (as defined in the Barbieri Employment Agreement),
    Mr. Barbieri is entitled to all accrued but unpaid base salary and any accrued but unused paid time-off to the date of the termination.
    </span></td></tr>
</table>

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Termination
    by the Company without Cause</i>: If the Company terminates Mr. Barbieri without Cause (as defined in the Barbieri Employment Agreement),
    Mr. Barbieri shall be paid all accrued but unpaid base salary and any accrued but unused paid time-off to the date of the termination.
    In the event Mr. Barbieri is terminated by the Company without Cause, including following a Change in Control (as defined by the
    Irani Employment Agreement), he will be eligible for severance pay that is equal to 12 months of Mr. Irani&#8217;s base bay, provided
    that he executes and does not revoke a customary general release of claims against the Company and its affiliates, officers, directors,
    agents, and employees (the &#8220;Severance Payment&#8221;). </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Termination
    by the Employee with Cause: </i>If Mr. Barbieri terminates his employment with the Company with Cause, including a termination with
    Cause following a Change in Control, he will be eligible for a Severance Payment. In the event of a termination of employment by
    Mr. Barbieri with Cause following a Change in Control, all unvested stock options previously issued to him shall become immediately
    vested and exercisable. </span></td></tr>
  </table>
<p style="text-align: center; margin-top: 0; margin-bottom: 0"></p>

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="text-align: center; margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OUTSTANDING
EQUITY AWARDS AT FISCAL YEAR-END</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="16" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Option Awards</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock Awards</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Name</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Grant Date</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Securities Underlying Unexercised Options (#) Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Securities Underlying Unexercised Options (#) Unexercisabe</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Option Exercise <br/>Price<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Option Expiration Date</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares or Units of Stock That Have Not Vested (#)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Market Value of Shares or Units of Stock That Have Not Vested ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 9%; text-align: center">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">3/24/2016</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">12,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">9.60</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 8%; text-align: center">3/24/2026</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">1/22/2018</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,375</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">31.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">1/22/2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">12/20/2018</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">18.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">12/20/2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">12/19/2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,625</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">22.48</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">12/19/2029</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Zackary Irani</td><td>&#160;</td>
    <td style="text-align: center">12/10/2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,827</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">50.88</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">12/10/2030</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">12/9/2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,375</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,125</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">35.68</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">12/9/2031</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">12/7/2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,563</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,562</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">13.36</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">4/20/2033</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">12/13/2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,844</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,531</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7.91</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">12/13/2033</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">12/13/2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78,438</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">3/24/2016</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,375</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9.60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">3/24/2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">1/22/2018</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,125</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">31.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">1/22/2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">12/20/2018</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">18.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">12/20/2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">12/19/2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">22.48</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">12/19/2029</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">Allen Barbieri</td><td>&#160;</td>
    <td style="text-align: center">12/10/2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">50.88</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">12/10/2030</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">12/9/2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,625</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">35.68</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">12/9/2031</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">12/7/2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">13.36</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">4/20/2033</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">12/13/2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7.91</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">12/13/2033</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">12/13/2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,513</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">4/6/2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">13.92</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">4/6/2033</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Gary Lu</td><td>&#160;</td>
    <td style="text-align: center">12/13/2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,844</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,531</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7.91</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">12/13/2033</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">12/13/2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,625</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51,769</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    vesting dates coincide with the option grant date annually for options held at the fiscal year-end.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    Mr. Zackary Irani, 25% of the option awards granted on 12/7/2023 vested immediately, while the remaining 75% will vest in equal installments
    over a 36-month period. The option awards granted to him on 1/22/2018 also vest in equal installments over a 36-month period. All
    other option awards granted to Mr. Zackary Irani vest in equal installments over a 48-month period. All RSU awards granted to Mr.
    Zackary Irani are subject to the same 48-month vesting schedule.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    Mr. Allen Barbieri, 100% of the option awards granted on 12/7/2023 vest immediately. All other share option awards granted to Mr.
    Allen Barbieri vest after a 12-month cliff date. All RSU awards granted to Mr. Allen Barbieri are subject to the same 12-month cliff.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    share option awards granted to Mr. Gary Lu vest in equal annual installments over a 4-year period. All RSU awards granted to Mr.
    Gary Lu are subject to the same 4-year vesting schedule.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEPENDENT
DIRECTOR COMPENSATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Independent Directors receive a cash component in addition to an equity component as part of their annual Board retainer fee. The cash
component of Board retainer fees is paid quarterly, while stock options typically vest on the one-year anniversary date of issuance.
The compensation of directors is subject to review and adjustment from time to time by the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
annual cash retainer fees are paid according to the following schedule:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">DIRECTOR COMPENSATION</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: left">Annual Cash Retainer</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">45,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Committee Chair Stipends:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Audit</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">15,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Compensation</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Nominating and Corporate Governance</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7,500</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the compensation of Independent Directors for the fiscal year ended May 31, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DIRECTOR
COMPENSATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Name</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fees Earned or Paid in Cash<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock Awards ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Option Awards Value ($) (1)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Non-Equity Incentive Plan Compensation<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Change in Pension Value and Nonqualified Deferred Compensation Earnings</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">All Other Compensation <br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total<br/> Value<br/> ($)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%; text-align: center">Catherine Coste</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">60,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">26,669</td><td style="width: 1%; text-align: left">(1)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">86,669</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">Jane Emerson, M.D., Ph.D.</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">52,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,669</td><td style="text-align: left">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">79,169</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">David Moatazedi</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">52,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,669</td><td style="text-align: left">(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">79,169</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 31px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
    fiscal year ended May 31, 2025, Ms. Catherine Coste had 22,125 option awards outstanding and 10,625 shares of restricted stock outstanding.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
    fiscal year ended May 31, 2025, Dr. Jane Emerson had 297,000 option awards outstanding and 10,625 shares of restricted stock outstanding. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
    fiscal year ended May 31, 2025, Mr. David Moatazedi had 132,000 option awards outstanding and 10,625 shares of restricted stock outstanding.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_004"></span>ITEM
12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth, as of September 26, 2025, certain information as to shares of Common Stock owned by (i) each person known
to beneficially own more than 5% of the outstanding Common Stock, (ii) each director, including director nominees, and each of our Named
Executive Officers (as defined under &#8220;Executive Compensation of Named Executive Officers&#8221;), and (iii) all executive officers
and directors of the Company as a group. Unless otherwise indicated, each person listed has sole voting and investment power over the
shares beneficially owned by him or her. Unless otherwise indicated, the address of each beneficial owner is 17571 Von Karman Avenue,
Irvine, California 92614.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5%
or Greater Stockholders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">NAME OF BENEFICIAL OWNER (1)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">SHARES BENEFICIALLY OWNED</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">PERCENTAGE BENEFICIALLY OWNED (1)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Zackary Irani</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">245,679</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">8.3</td><td style="width: 1%; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Directors
and Named Executive Officers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">NAME OF BENEFICIAL OWNER (1)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">SHARES BENEFICIALLY OWNED</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">PERCENTAGE BENEFICIALLY OWNED (1)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Zackary Irani (2)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">245,679</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">8.3</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Allen Barbieri (3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71,668</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.5</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Jane Emerson, M.D., Ph.D. (4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52,875</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Gary Lu (5)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,469</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.1</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">David Moatazedi (6)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,563</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.9</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Eric Bing Chin (7)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0.0</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">All executive officers and directors as a group (six persons)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">475,103</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16.2</td><td style="text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">* </span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Percentage of shares
                                                                                                                                                               beneficially owned does not exceed 1.0% of our outstanding shares of Common Stock.</span></td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial ownership
is determined in accordance with Rule 13d-3 of the Securities Exchange Act of 1934. Any shares of Common Stock that each named person
and group has the right to acquire within 60 days pursuant to options, warrants, conversion privileges or other rights, are deemed outstanding
for purposes of computing shares beneficially owned by and the percentage ownership of each such person and group. However, such shares
are not deemed outstanding for purposes of computing the shares beneficially owned by or percentage ownership of any other person or
group. Percentage ownership for each named beneficial owner, and the ownership of the directors and executive officers as a group, is
based on 2,869,900 shares outstanding as of September 26, 2025, plus the shares the named person and group has a right to acquire within
60 days thereafter pursuant to options, warrants, conversion privileges or other rights and privileges.</span></td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 245,679
shares underlying options exercisable by Mr. Zackary Irani at or within 60 days of September 26, 2025.</span></td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 71,668
shares underlying options exercisable by Mr. Allen Barbieri at or within 60 days of September 26, 2025.</span></td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 52,875
shares underlying options exercisable by Dr. Jane Emerson at or within 60 days of September 26, 2025.</span></td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 30,469
shares underlying options exercisable by Mr. Gary Lu at or within 60 days of September 26, 2025.</span></td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 25,563
shares underlying options exercisable by Mr. David Moatazedi at or within 60 days of September 26, 2025.</span></td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Eric Bing Chin
joined the Board in June 2025. He has no stock options that are exercisable at or within 60 days of September 26, 2025.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity
Compensation Plan Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information as of May 31, 2025 relating to all our equity compensation plans:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Plan category</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of <br/> securities to<br/> be issued upon<br/> exercise<br/> of outstanding<br/> options or rights</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average<br/> exercise price of<br/> outstanding<br/> options or rights</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of securities<br/> remaining available<br/> for future issuance under equity compensation plans</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Equity compensation plans approved by security holders</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">413,866</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">19.29</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">153,038</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Equity compensation plans not approved by security holders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">413,866</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">19.29</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">153,038</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_005"></span>ITEM
13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain
Relationships and Related Transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board reviews, approves, and/or ratifies all transactions involving related persons. The purpose of the review is to determine that such
transactions are not conducted on terms that are materially less favorable to the Company than what would be usual and customary in transactions
between unrelated persons and, in the case of transactions involving directors, to determine whether such transactions affect the independence
of a director in accordance with the relevant rules and standards issued by the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than as described under the headings &#8220;Executive Compensation&#8221; and &#8220;Director Compensation&#8221; in Item 11 of this
Amendment, since June 1, 2024, there has not been, and there is not currently proposed, any transaction, arrangement or relationship
or series of similar transactions, arrangements or relationships, in which:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            or our subsidiaries were or will be a participant;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            amount involved exceeded or exceeds $120,000; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            of our directors, executive officers, beneficial owners of more than 5% of any class of our
                                            voting securities, any member of the immediate family of any such director or executive officer,
                                            or any person (other than a tenant or employee) sharing the household of any such director
                                            or executive officer had or will have a direct or indirect material interest.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director
Independence</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
&#8220;Item 10. Directors, Executive Officers and Corporate Governance; Corporate Governance, Board Composition&#8221; above for a discussion
regarding the independence of the members of our Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_006"></span>ITEM
14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
approximate aggregate fees billed for professional services by our auditors in the fiscal years ended May 31, 2025 and 2024 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">FISCAL YEAR</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">FISCAL YEAR</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2025</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2024</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">FEES</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">($)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">($)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-weight: bold; font-style: italic">Audit Fees(1)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">163,650</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">154,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left">Audit and review of the financial statements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic">Tax Fees(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,037</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,887</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left">Tax Consulting Services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; font-weight: bold; text-align: left">All Other Fees(3)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">8,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">23,040</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; font-weight: bold">Total</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">192,687</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">177,040</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit Fees consist
of the aggregate fees billed for professional services rendered for the audit of our annual consolidated financial statements, the reviews
of the consolidated financial statements included in our Forms 10-Q, and for any other services that are normally provided by our auditors
in connection with our statutory and regulatory filings or engagements.</span></td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax Fees consist
of the aggregate fees billed for professional services rendered for tax compliance, tax advice, and tax planning. The Company did not
incur any tax fees from H&amp;W for fiscal years 2024 and 2025.</span></td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All Other Fees
consist of the aggregate fees billed for products and services provided by our auditors and not otherwise included in Audit Fees, Audit
Related Fees, or Tax Fees. These include services such as issuing a Comfort Letter for the ATM offering and providing consent for the
Form S-3 filing.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee has considered that the provision of the above services has not impaired the principal accountant&#8217;s ability to
maintain independence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is the policy of the Audit Committee that all audit and permissible non-audit services provided by our independent registered public
accounting firm and related fees paid to our independent registered public accounting firm must be approved in advance by the Audit Committee
on a case-by-case basis. All of the above-described services provided by our auditors were approved in advance by the Audit Committee
under Item 2-01(c)(7)(i)(C) of Regulation S-X.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_007"></span>PART
IV</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_008"></span>ITEM
15. EXHIBITS LIST AND FINANCIAL SCHEDULES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following documents are filed as part of this Annual Report on Form 10-K:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: right"/>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Consolidated
    Financial Statements</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to Item 15(a)(1) of the 2024 Annual Report.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: right"/>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Consolidated
    Financial Statement Schedules</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to Item 15(a)(2) of the 2024 Annual Report.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: right"/>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Exhibits</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
    below.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
    No.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0"><a href="https://www.sec.gov/Archives/edgar/data/73290/000102140800002832/0001021408-00-002832-0002.txt" style="-sec-extract: exhibit">Amended and Restated Certificate of Incorporation of Registrant filed with the Secretary of State of Delaware on August 1, 2000 (incorporated by reference to Exhibit 3.8 filed with the Registrant&#8217;s Annual Report on Form 10-KSB for the fiscal year ended May 31, 2000).</a></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/73290/000151316223000117/exhibit3_1.htm" style="-sec-extract: exhibit">Amended
    and Restated Bylaws, as adopted on July 24, 2023 (incorporated by reference to Exhibit 3.1 of the Company&#8217;s Form 8-K filed
    July 26, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/73290/000164117225004976/ex3-1.htm" style="-sec-extract: exhibit">Certificate
    of Amendment to the Company&#8217;s Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of
    the Company&#8217;s Form 8-K filed April 16, 2025).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/73290/000089256999002463/0000892569-99-002463.txt" style="-sec-extract: exhibit">Specimen
    Stock Certificate of Common Stock of Registrant (incorporated by reference to Exhibit 4.1 filed with Registrant&#8217;s Registration
    Statement on Form SB-2, Commission No. 333-87231 filed on September 16, 1999).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex4-2.htm">Description of Capital Stock.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/73290/000101968709003694/lease1.htm" style="-sec-extract: exhibit">Standard
    Industrial/Commercial Single-Tenant Lease, dated June 18, 2009, by and between Registrant and CNH, LLC for 17571 Von Karman Avenue,
    Irvine, CA 92614 (incorporated by reference to Exhibit 10.1 of the Company&#8217;s August 31, 2009 Form 10-Q filed October 16, 2009).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/73290/000151316214000555/def14a.htm" style="-sec-extract: exhibit">2014
    Stock Incentive Plan of Registrant (incorporated by reference to Exhibit A of the Company&#8217;s Definitive Proxy Statement filed
    with the Securities and Exchange Commission on September 29, 2014).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/73290/000151316217000270/def14a.htm" style="-sec-extract: exhibit">2017
    Stock Incentive Plan of Registrant (incorporated by reference to Exhibit A of the Company&#8217;s Definitive Proxy Statement filed
    with the Securities and Exchange Commission on September 28, 2017).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/73290/000151316220000207/def14a.htm" style="-sec-extract: exhibit">2020
    Stock Incentive Plan of Registrant (incorporated by reference to Exhibit A of the Company&#8217;s Definitive Proxy Statement filed
    with the Securities and Exchange Commission on September 25, 2020).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/73290/000149315223030254/ex10-6.htm" style="-sec-extract: exhibit">Employment
    Agreement, dated March 1, 2023, by and between Biomerica, Inc. and Gary Lu (incorporated by reference to Exhibit 10.6 of the Company&#8217;s Form
10-K filed August 25, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/73290/000149315223034447/formdef14a.htm" style="-sec-extract: exhibit">2023
    Stock Incentive Plan of Registrant (incorporated by reference to Exhibit A of the Company&#8217;s Definitive Proxy Statement filed
    with the Securities and Exchange Commission on September 27, 2023 ).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">10.7</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/73290/000149315224038820/formdef14a.htm" style="-sec-extract: exhibit">2024 Stock Incentive Plan of Registrant (incorporated by reference to Exhibit A of the Company&#8217;s Definitive Proxy Statement filed with the Securities and Exchange Commission on September 30, 2024).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/73290/000149315224034208/ex10-8.htm" style="-sec-extract: exhibit">Employment Agreement dated August 28, 2024 by and between Biomerica Inc. and Gary Lu (incorporated by reference to Exhibit 10.8 of the Company&#8217;s Form
10-K filed August 28, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/73290/000149315225002209/ex10-1.htm" style="-sec-extract: exhibit">Employment Agreement dated January 13, 2025 by and between Biomerica Inc. and Zackary S. Irani (incorporated by reference to Exhibit 10.1 of the Company&#8217;s
Form 8-K filed January 14, 2025).</a></span></p></td></tr>
</table>

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="text-align: center; margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/73290/000149315225002209/ex10-2.htm" style="-sec-extract: exhibit">Employment
                                                                              Agreement dated January 13, 2025 by and between Biomerica Inc. and Allen Barbieri (incorporated by reference to Exhibit 10.2 of the Company&#8217;s Form 8-K filed January 14, 2025).</a></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">19.1</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex19-1.htm">Insider Trading Policy</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/73290/000149315223030254/ex21-1.htm" style="-sec-extract: exhibit">List of Subsidiaries (incorporated by reference to Exhibit 21.1 of the Company&#8217;s
Form 10-K filed August 29, 2025).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/73290/000164117225026041/ex23-1.htm" style="-sec-extract: exhibit">Consent of Independent Registered Public Accounting Firm (Haskell &amp; White LLP) (incorporated by reference to Exhibit 23.1 of the Company&#8217;s Form 10-K filed August 29, 2025).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/73290/000164117225026041/ex31-1.htm" style="-sec-extract: exhibit">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) under the Exchange Act, adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, as amended (incorporated by reference to Exhibit 31.1 of the Company&#8217;s Form 10-K filed August 29, 2025).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/73290/000164117225026041/ex31-2.htm" style="-sec-extract: exhibit">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) under the Exchange Act, adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, as amended (incorporated by reference to Exhibit 31.2 of the Company&#8217;s Form 10-K filed August 29, 2025).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">31.3</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex31-3.htm">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) under the Exchange Act, adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, as amended.</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">31.4</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex31-4.htm">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) under the Exchange Act, adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, as amended.</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/73290/000164117225026041/ex32-1.htm" style="-sec-extract: exhibit">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, as amended (incorporated by reference to Exhibit 32.1 of the Company&#8217;s Form 10-K filed August 29, 2025).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/73290/000164117225026041/ex32-2.htm" style="-sec-extract: exhibit">Certification of Chief Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, as amended (incorporated by reference to Exhibit 32.2 of the Company&#8217;s Form 10-K filed August 29, 2025).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">97.1</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex97-1.htm">Compensation Recovery Policy, effective November 17, 2023.</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
certifications attached as Exhibits 32.3 and 32.4 accompany this Annual
Report pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, as amended, and shall
not be deemed &#8220;filed&#8221; by the registrant for purposes of Section 18 of the Exchange Act and are not to be incorporated by reference
into any of the registrant&#8217;s filings under the Securities Act or the Exchange Act, irrespective of any general incorporation language
contained in any such filing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_009"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BIOMERICA,
    INC.</b></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
    </span></td>
    <td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Zackary S. Irani</i></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zackary
    S. Irani,</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    September 26, 2025</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 21; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>ex4-2.htm
<DESCRIPTION>EX-4.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><B>Exhibit 4.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DESCRIPTION
OF CAPITAL STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of all material characteristics of the capital stock of Biomerica, Inc. as set forth in our First Amended and
Restated Certificate of Incorporation (our &ldquo;<U>Charter</U>&rdquo;), Amended and Restated Bylaws (our &ldquo;<U>Bylaws</U>&rdquo;),
Series A Certificate of Designation, as corrected (the &ldquo;<U>Certificate of Designation</U>&rdquo;), and certain provisions of the
General Corporation Law of the State of Delaware (the &ldquo;<U>DGCL</U>&rdquo;). The summary does not purport to be complete and is
qualified in its entirety by reference to our Charter, Bylaws, and Certificate of Designation, copies of which have been filed as exhibits
to our public filings with the Securities and Exchange Commission, and applicable provisions of the DGCL. References to &ldquo;we,&rdquo;
&ldquo;our,&rdquo; &ldquo;us,&rdquo; or the &ldquo;Company&rdquo; refer to Biomerica, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>General</I>.
We may issue shares of our common stock from time to time. We are authorized to issue 25,000,000 shares of our common stock, par value
$0.08 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting
Rights</I>. The holders of common stock are entitled to one vote for each share held of record on all matters submitted to a vote of
the stockholders. The holders of common stock are not entitled to cumulative voting rights with respect to the election of directors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dividends</I>.
Subject to preferences that may be applicable to any shares of preferred stock issued in the future, holders of common stock are entitled
to receive dividends on a pro rata basis out of funds legally available at the times and in the amounts that our board of directors may
determine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Rights
to Receive Liquidation Distributions</I>. In the event of a liquidation, dissolution or winding up of our Company holders of our common
stock are entitled to share ratably in all assets remaining after payment of liabilities and the liquidation preference of any then outstanding
preferred stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>No
Preemptive or Similar Rights</I>. Holders of common stock have no preemptive rights and no right to convert their common stock into any
other securities. There are no redemption or sinking fund provisions applicable to the common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of our Charter, our board of directors is authorized, subject to limitations prescribed by Delaware law, to issue up to
5,000,000 shares of preferred stock, par value $0.08 per share, in one or more series, to establish from time to time the number of shares
to be included in each series, and to fix the designation, powers, preferences and rights of the shares of each series and any of its
qualifications, limitations or restrictions, in each case without further action by our stockholders. Our board of directors also can
increase or decrease the number of shares of any series of preferred stock, but not below the number of shares of that series then outstanding.
Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the
voting power or other rights of the holders of our common stock. The issuance of preferred stock, while providing flexibility in connection
with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing
a change in our control or the removal of management and could adversely affect the market price of our common stock and the voting and
other rights of the holders of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Series
A Preferred Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>General</I>.
On February 4, 2020, we filed a Certificate of Designations, Preferences and Rights of Series A 5% Convertible Preferred Stock with the
Secretary of State of the State of Delaware, which designated 571,429 of our preferred stock as Series A Preferred Stock (the &ldquo;<U>Series
A Preferred Stock</U>&rdquo;). Those shares of Series A Preferred Stock have since been converted into common stock and are no longer
outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting
Rights</I>. Except as otherwise provided by the DGCL, other applicable law or as provided in the Certificate of Designations, the holders
of our Series A Preferred Stock are not entitled to vote on any matter submitted for a vote of holders of our common stock. The consent
of the holders of at least a majority of the outstanding shares of our Series A Preferred Stock will be required to, among other matters,
(i) alter, amend or change adversely any rights, preferences, or privileges of our Series A Preferred Stock, (ii) amend our First Amended
and Restated Certificate of Incorporation or Bylaws in any manner that would impair or reduce the rights of our Series A Preferred Stock,
or (iii) amend, alter, or repeal any provision of the Certificate of Designations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dividends</I>.
Shares of our Series A Preferred Stock accrue annual preferred dividends at a rate of $0.175 per share, which are payable when, as and
if declared by our board of directors. The holders of the outstanding shares of our Series A Preferred Stock are also entitled to receive
on each share of our Series A Preferred Stock dividends prior to, or simultaneously with, any dividend declared with respect to our common
stock equal to the greater of (i) the amount of dividends that have accrued on such share of our Series A Preferred Stock and (ii) the
dividend payable with respect to each share of our common stock issuable upon conversion of such share of our Series A Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Rights
to Receive Liquidation Distributions</I>. In the event of a liquidation, dissolution or winding up of the Company, or a Deemed Liquidation
Event (as defined in the Certificate of Designation) the holders of our Series A Preferred Stock are eligible to receive the greater
of (i) an amount equal to $3.50 per share (subject to appropriate adjustment in the event of any stock dividend, stock split, combination,
or other similar recapitalization with respect to our Series A Preferred Stock) (the &ldquo;<U>Original Issue Price</U>&rdquo;), plus
an amount equal to accrued and unpaid dividends thereon, or (ii) such amount per share as would have been payable had all shares of our
Series A Preferred Stock been converted into our common stock immediately prior to such liquidation, dissolution, winding up or Deemed
Liquidation Event.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Conversion</I>.
Shares of our Series A Preferred Stock are convertible at the option of the holder at any time into shares of our common stock at a conversion
rate determined by dividing the Original Issue Price by $3.50 per share (subject to appropriate adjustment in the event of any stock
dividend, stock split, combination, recapitalizations, dividends, distributions and certain issuances of common stock) (the &ldquo;<U>Conversion
Price</U>&rdquo;). This formula initially results in a one-to-one conversion ratio. The Conversion Price is subject to customary weighted
average anti-dilution adjustments in the event of certain dilutive issuances of shares of our common stock or convertible securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may require the conversion of all of the outstanding shares of our Series A Preferred Stock if the closing sale price of our common stock
equals or exceeds $9.00 for a period of five (5) consecutive trading days with a minimum average trading volume of 35,000 shares per
day over such period; provided, that, on such date, the shares of our common stock issuable upon conversion of our Series A Preferred
Stock are registered for resale under the Securities Act or are otherwise eligible for resale pursuant to Rule 144 thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the foregoing, prior to the receipt of all approvals, if any, of the shareholders of the Company necessary for purposes of the rules
and regulations of the applicable trading market, our Series A Preferred Shares shall not be converted into shares of common stock: (i)
in the aggregate into more than 19.99% of the shares of common stock outstanding immediately prior to the issuance date, subject to appropriate
adjustment in the event of a stock split, stock dividend, combination or other similar recapitalization, or (ii) by any beneficial holder
(as such term is defined under Rule 13d-3 of the Exchange Act) or &ldquo;group&rdquo; (as such term is defined under Rule 13d-5 of the
Exchange Act) (such beneficial holder or group, a &ldquo;<U>Capped Holder</U>&rdquo;), if (A) the aggregate number of shares of common
stock issued to such Capped Holder upon such conversion and any conversion shares then held by the Capped Holders, plus (B) the number
of shares of common stock underlying our Series A Preferred Shares that would be held at such time by the Capped Holders (after giving
effect to such conversion), plus (C) the aggregate number of shares of common stock held by such Capped Holder as of immediately prior
to the issuance date, would in the aggregate exceed more than 19.99% of the shares of common stock outstanding immediately prior to the
issuance date (without regard to any limitation on conversion pursuant to this Section 5(n)), then such Capped Holder shall be entitled
to convert such number of our Series A Preferred Shares as would result in the sum of clauses (A), (B) and (C) (after giving effect to
such conversion) being equal to 19.99% of the shares of common stock outstanding immediately prior to the issuance date, in each case,
subject to appropriate adjustment in the event of a stock split, stock dividend, combination or other similar recapitalization. Any Series
A Preferred Shares which a holder has elected to convert but which, by reason of the previous sentence are not so converted, shall be
treated as if the holder had not made such election to convert and such Series A Preferred Shares shall remain outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware
Law and Certain Charter and Bylaw Provisions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
provisions of DGCL, as well as certain terms of our Charter and Bylaws, may have the effect of delaying, deferring or discouraging another
person from acquiring control of us by means of a tender offer, a proxy contest or otherwise, or removing incumbent officers and directors.
These provisions, some of which are summarized below, are expected to discourage certain types of coercive takeover practices and takeover
bids that our board of directors may consider inadequate and to encourage any person seeking to acquire control of us to first negotiate
with our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Delaware
Law</I>. We are governed by the provisions of Section 203 of the DGCL. In general, Section 203 prohibits a public Delaware corporation
from engaging in a &ldquo;business combination&rdquo; with an &ldquo;interested stockholder&rdquo; for a period of three years after
the date such stockholder became an &ldquo;interested stockholder&rdquo;. A &ldquo;business combination&rdquo; includes mergers, asset
sales or other transactions resulting in a financial benefit to the stockholder. An &ldquo;interested stockholder&rdquo; is a person
who, together with affiliates and associates, owns, or within three years did, prior to the determination of interested stockholder status,
own, 15% or more of the corporation&rsquo;s outstanding voting stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 42.85pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Charter
and Bylaw Provisions. </I>Each of our Charter and Bylaws include a number of other provisions that may have the effect of deterring hostile
takeovers or delaying or preventing changes in control or our management, including the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Issuance
                                            of Undesignated Preferred Stock</I>. Our board of directors has the authority, to issue up
                                            to 5,000,000 shares of our preferred stock with rights and preferences designated from time
                                            to time by our board of directors, 571,429 of which have been designated as Series A Preferred
                                            Stock, and none of which are outstanding.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>No
                                            Cumulative Voting</I>. The DGCL provides that stockholders are denied the right to cumulate
                                            votes in the election of directors unless our Charter provides otherwise. Our Charter does
                                            not provide for cumulative voting.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Size
                                            of Board and Vacancies</I>. Our Charter and Bylaws provide that the number of directors on
                                            our board of directors shall consist of not less than three nor more than nine members as
                                            fixed from time to time by resolution of our board of directors. Newly created directorships
                                            resulting from any increase in our authorized number of directors, and any vacancies resulting
                                            from death, resignation, retirement, disqualification, removal from office or other cause,
                                            will generally be filled by a majority of the remaining members of our board of directors
                                            then in office.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 42.85pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I></I></FONT></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>
<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>3
<FILENAME>ex19-1.htm
<DESCRIPTION>EX-19.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
19.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BIOMERICA,
INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">POLICY
ON INSIDER TRADING</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EFFECTIVE
AS OF November 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the course of conducting the business of Biomerica, Inc. (the &ldquo;Company&rdquo;), you may come into possession of material information
about the Company or other entities that is not available to the investing public. You have a legal and ethical obligation to maintain
the confidentiality of material nonpublic information. In addition, it is illegal by state and Federal law, and a violation of Company
policy, to purchase or sell securities of the Company or any other entity while you are in possession of material nonpublic information
about the Company or that other entity. The Company&rsquo;s Board of Directors has adopted this Policy in order to ensure compliance
with the law and to avoid even the appearance of improper conduct by anyone associated with the Company. We have all worked hard to establish
the Company&rsquo;s reputation for integrity and ethical conduct, and we are all responsible for preserving and enhancing this reputation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Scope
of Coverage</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
restrictions set forth in this Policy apply to all Company officers, directors and employees and consultants (&ldquo;Company Associates&rdquo;),
wherever located, and to their spouses, minor children, adult family members sharing the same household and any other person or entity
over whom the officer, director or employee exercises substantial influence or control over his, her or its securities trading decisions
(&ldquo;Key Family Members&rdquo;). This Policy also applies to any trust or other estate in which an officer, director or employee has
a substantial beneficial interest or as to which he or she serves as trustee or in a similar fiduciary capacity. The Company may also
determine that other persons should be subject to this Policy, such as contractors or consultants who have access to material nonpublic
information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy applies to purchase or sale transactions in the Company&rsquo;s common stock, or in the common stock or preferred stock, bonds,
options to purchase common stock, warrants, and other derivative securities that are not issued by the Company, such as exchange-traded
put or call options relating to the Company&rsquo;s securities (the &ldquo;Company&rsquo;s Securities&rdquo;), or another entity&rsquo;s
securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
avoid even the appearance of impropriety, and to assist you with ensuring you are not engaging in inappropriate trading of the Company&rsquo;s
securities, we have implemented the following procedures:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Pre-Clearance
Procedures</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
Company Associates and their Key Family Members, wishing to engage in any transaction involving the Company&rsquo;s securities (including
the exercise of stock options, gifts, contributions to a trust, or any other transfers) must first obtaining pre-clearance of the transaction
from the Company&rsquo;s Chief Executive Officer, Chief Financial Officer or Executive Vice-Chairman (each an &ldquo;Executive Officer&rdquo;):
Each proposed transaction will be evaluated to determine if it raises insider trading concerns or other concerns under federal laws and
regulations. Any advice will relate solely to the restraints imposed by law and will not constitute advice regarding the investment merits
of any transaction. Clearance of a transaction is valid only for a 48-hour period. If the transaction order is not placed within that
48-hour period, clearance of the transaction must be re-requested. If clearance is denied, the fact of such denial must be kept confidential
by the person requesting such clearance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
a request for pre-clearance is made by a Company Associate and their Key Family Members, the requestor should carefully consider whether
he or she may be aware of any material nonpublic information about the Company, and should describe fully those circumstances with an
Executive Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Blackout
Periods</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
Officers, members of the Board of Directors, and key employees (&ldquo;Key Insiders&rdquo;) whose jobs give them access to the Company&rsquo;s
sales, costs, earnings strategic discussions, litigations and other nonpublic information, shall be subject to certain blackout periods
during which they shall be precluded from engaging in any trading on the Company&rsquo;s Securities. If there is a question as to whether
you are a Key Insider, please contact an Executive Officer for guidance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Quarterly
Blackout</B>: Because the announcement of the Company&rsquo;s quarterly and year-end financial results will almost always have the potential
to have a material effect on the market price of the Company&rsquo;s Securities, you may not trade in the Company&rsquo;s Securities
during the following periods:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.35pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1st
                                            Fiscal Quarter &ndash; Beginning on August 20 and continuing through 48 hours after the Company&rsquo;s
                                            earnings release for the first fiscal quarter.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2<SUP>nd</SUP>
                                            Fiscal Quarter &ndash; Beginning on November 20 and continuing through 48 hours after the
                                            Company&rsquo;s earnings release for the second fiscal quarter.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3<SUP>rd</SUP>
                                            Fiscal Quarter &ndash; Beginning on February 20 and continuing through 48 hours after the
                                            Company&rsquo;s earnings release for the third fiscal quarter.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4<SUP>th</SUP>
                                            Fiscal Quarter &ndash; Beginning on May 20 and continuing through 48 hours after the Company&rsquo;s
                                            earnings release for the fourth fiscal quarter.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Interim
Earnings Guidance Blackout</B>: The Company may on occasion issue interim earnings guidance or other potentially material information
by means of a press release, SEC filing on Form 8-K or other means designed to achieve widespread dissemination of the information. You
should anticipate that trading will be blacked out while the Company is in the process of assembling the information to be released and
until the information has been released and fully absorbed by the market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Event-Specific
Blackout</B>. From time to time, an event may occur that is material to the Company and is known by only a few directors, officers, and/or
Key Employees. The existence of an event-specific blackout will not be announced. If, however, a person whose trades are subject to pre-clearance
requests permission to trade in the Company&rsquo;s securities during an event-specific blackout, an Executive Officer will inform the
requesting person of the existence of a blackout period, without disclosing the reason for the blackout. Any person made aware of the
existence of an eventspecific blackout should not disclose the existence of the blackout to any other person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTE:
Even if a blackout period is not in effect, at no time may you trade in Company securities if you are in possession of material nonpublic
information about the Company. The failure of an Executive Officer to notify you of an event-specific blackout will not relieve you of
the obligation not to trade while in possession of material nonpublic information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Individual
Responsibility </U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
Company Associates are individually responsible for complying with this Policy and ensuring the compliance of their Key Family Members
to this Policy. Accordingly, you should make your family and household members aware of the need to confer with you before they trade
in Company Securities, and you should treat all such transactions for the purposes of this Policy and applicable securities laws as if
the transactions were for your own account.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Material
Nonpublic Information</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>What
is Material Information</B>? Under Company policy and United States laws, information is material if there is a substantial likelihood
that a reasonable investor would consider the information important in determining whether to trade in a security; or if the information,
if made public, likely would affect the market price of a company&rsquo;s securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
may be material even if it is significant only when considered in combination with publicly available information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>What
is Nonpublic Information</B>? Information is considered to be nonpublic unless it has been adequately disclosed to the public, which
means that the information must be publicly disseminated, and sufficient time must have passed for the securities markets to digest the
information. It is important to note that information is not necessarily public merely because it has been discussed in the press, which
will sometimes report rumors. You should presume that information is nonpublic unless you can point to its official release by the Company
in at least one of the following ways:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">public
                                            filings with securities regulatory authorities;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">issuance
                                            of press releases;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">meetings
                                            with members of the press and the public; or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">information
                                            contained in proxy statements and prospectuses.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may not attempt to &ldquo;beat the market&rdquo; by trading simultaneously with, or shortly after, the official release of material information.
Although there is no fixed period for how long it takes the market to absorb information, out of prudence a person in possession of material
nonpublic information should refrain from any trading activity for two full trading days following its official release.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>&ldquo;Tipping&rdquo;
Material Nonpublic Information Is Prohibited</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to trading while in possession of material nonpublic information, it is also illegal and a violation of the Company&rsquo;s
Insider Trading Policy, as well as the Company&rsquo;s Code of Business Conduct and Ethics, to convey such information to another (&ldquo;tipping&rdquo;)
if you know or have reason to believe that the person will misuse such information by trading in the Company&rsquo;s Securities or passing
the information to others who will trade. This applies regardless of whether the person or entity being &ldquo;tipped&rdquo; is related
to the insider or is an entity, such as a trust or a corporation, and regardless of whether you receive any monetary benefit from person
or entity being tipped.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Special
Transactions</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading restrictions in this Policy do not apply in the case of the following transactions, except as specifically noted:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1)</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock
                                            Option Plans:</B> The trading restrictions in this Policy do not apply to exercises of stock
                                            options where no Company common stock is sold in the market to fund the option exercise price
                                            or related taxes. Conversely, these trading restrictions do apply, to sales for any reason
                                            of Company common stock received upon the exercise of options, including sales to fund the
                                            option exercise price (i.e., a cashless exercise of options) or related taxes.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2)</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Restricted
                                            Stock Awards</B>: The trading restrictions in this Policy do not apply to the vesting of
                                            restricted stock, or the exercise of a tax withholding right pursuant to which you elect
                                            to have the Company withhold shares of stock to satisfy tax withholding requirements upon
                                            the vesting of any restricted stock. However, the trading restrictions do apply, to any market
                                            sale of restricted stock.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3)</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
                                            Similar Transactions</B>: Any other purchase of Company securities directly from the Company
                                            or sales of Company securities directly to the Company are not subject to the trading restrictions
                                            of this Policy.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4)</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Gifts
                                            of Securities: </B>Bona fide gifts of securities are not transactions subject to this Policy,
                                            unless the person making the gift knows that the recipient intends to sell the Company securities
                                            while the officer, director, or employee is aware of material nonpublic information. The
                                            timing of gifts of securities should be discussed and cleared with an Executive Officer of
                                            the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Restricted
Transactions:</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the heightened legal risk associated with the following transactions, the individuals subject to this Policy may not engage in the
following transactions without obtaining preclearance from an Executive Officer:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1)</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Short
                                            Sales</B>. Absent preclearance, you may not engage in short sales of Company securities.
                                            A short sale has occurred if the seller: (a) does not own the securities sold; or (b) does
                                            own the securities sold, but does not deliver them within 20 days or place them in the mail
                                            within 5 days of the sale. Short sales may reduce a seller&rsquo;s incentive to seek to improve
                                            the Company&rsquo;s performance, and often have the potential to signal to the market that
                                            the seller lacks confidence in the Company&rsquo;s prospects.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2)</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Margin
                                            Accounts and Pledges.</B> Because a margin sale or foreclosure sale may occur at a time when
                                            the pledgor is aware of material nonpublic information or otherwise is not permitted to trade
                                            in Company securities, absent preclearance, you may not hold Company securities in a margin
                                            account or otherwise pledge Company securities as collateral for a loan.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3)</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Hedging
                                            Transactions. </B>Absent preclearance, you may not engage in hedging transactions such as
                                            (but not limited to) zero-cost collars, equity swaps, and forward sale contracts. Hedging
                                            transactions may allow a director, officer, or employee to continue to own Company securities,
                                            but without the full risks and rewards of ownership. This may lead to the director, officer,
                                            or employee no longer having the same objectives as the Company&rsquo;s other shareholders.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Reporting
Violations/Seeking Advice</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should refer suspected violations of this Policy to an Executive Officer. In addition, if you: a) receive material nonpublic information
that you are not authorized to receive or that you do not legitimately need to know to perform your employment responsibilities, or b)
receive confidential information and are unsure if it is within the definition of material nonpublic information or whether its release
might be contrary to a fiduciary or other duty or obligation, you should not share it with anyone. To seek advice about what to do under
those circumstances, you should contact an Executive Officer before discussing the information with any colleagues as this may exacerbate
the problem. Containment of all material non-public information, until it has been legally disseminated to the general market is critical.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Post-Termination
Transactions</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy, continues to apply to transactions in Company securities even after termination of service with the Company. If an individual
is in possession of material nonpublic information when his or her service terminates, that individual may not trade in Company securities
until that information has become public or is no longer material. The preclearance procedures specified herein will cease to apply to
transactions in Company securities upon the expiration of any blackout period or other Company-imposed trading restrictions applicable
at the time of the termination of service, and following the full public release of all material non-pubic information in possession
of the former employee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Penalties
for Violations of the Insider Trading Policy and Laws</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States and many other countries, the personal consequences to you of illegal insider trading can be severe. In addition to
injunctive relief, disgorgement, and other ancillary remedies, U.S. law empowers the government to seek significant civil penalties against
persons found liable of insider trading, including as tippers or tippees. The amount of a penalty could total three times the profits
made or losses avoided. All those who violate U.S. insider trading laws, including tippers, could be subject to the maximum penalty.
The maximum penalty may be assessed even against tippers for the profits made or losses avoided by all direct and remote persons who
have been tipped.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Criminal
penalties may also be assessed for insider trading. Any person who &ldquo;willfully&rdquo; violates any provision of the Securities Exchange
Act of 1934 (or rule promulgated thereunder) may be fined up to $5 million ($25 million for entities) and/or imprisoned for up to twenty
years. Subject to applicable law, Company employees who violate this Policy may also be subject to discipline by the Company, up to and
including termination of employment, even if the country or jurisdiction where the conduct took place does not regard it as illegal.
Needless to say, a violation of law, or even an SEC investigation that does not result in prosecution, can tarnish a person&rsquo;s reputation
and irreparably damage a career. If you are located or engaged in dealings outside the U.S., be aware that laws regarding insider trading
and similar offenses differ from country to country. Employees must abide by the laws in the country where located. However, you are
required to comply with this Policy even if local law is less restrictive. If a local law conflicts with the Company&rsquo;s Insider
Trading Policy, you are required to consult an Executive Officer before trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy replaces and supersedes all prior policies pertaining to the purchase and sale of Company Securities, and in the securities of
other companies with whom Biomerica is in material undisclosed discussions. If you have any questions pertaining to the ownership or
trading in the Company&rsquo;s Securities, please contact an Executive Officer for guidance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Acknowledgement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
employees must acknowledge their understanding of, and intent to comply with, this Insider Trading Policy by signing below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature: </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name: </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date:&nbsp;&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.3
<SEQUENCE>4
<FILENAME>ex31-3.htm
<DESCRIPTION>EX-31.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
31.3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF CHIEF EXECUTIVE OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Zackary S. Irani, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have reviewed this Amendment No.1 to the Annual Report on Form 10-K/A of Biomerica, Inc.; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Zackary S. Irani</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Zackary
    S. Irani</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    September 26, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.4
<SEQUENCE>5
<FILENAME>ex31-4.htm
<DESCRIPTION>EX-31.4
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
31.4</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF CHIEF FINANCIAL OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Gary Lu, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have reviewed this Amendment No. 1 to the Annual Report on Form 10-K/A of Biomerica, Inc.; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Gary Lu</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary
    Lu</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    September 26, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>6
<FILENAME>ex97-1.htm
<DESCRIPTION>EX-97.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
97.1</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">BIOMERICA,
INC.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">COMPENSATION
RECOVERY POLICY</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors (the &ldquo;<B>Board</B>&rdquo;) of Biomerica, Inc. (the &ldquo;<B>Company</B>&rdquo;) has adopted this Compensation
Recovery Policy (this &ldquo;<B>Policy</B>&rdquo;) to comply with Section 10D and Rule 10D-1 of the Exchange Act and the Listing Rules
of The Nasdaq Stock Market (the &ldquo;<B>Rules</B>&rdquo;), and to establish the circumstances under which the Company shall seek recoupment
and forfeiture of Incentive-Based Compensation Received by Executive Officers of the Company in the event of an Accounting Restatement.
The Board believes the adoption of this Policy is consistent with the Company&rsquo;s executive compensation philosophy and objectives,
and in furtherance of the Board&rsquo;s intention to follow sound corporate governance practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Policy was adopted by the Board on November 17, 2023 (the &ldquo;<B>Effective Date</B>&rdquo;). The Board has delegated to the Compensation
Committee the responsibility of administering this Policy. Except as specifically set forth in <U>Section 2</U> (which sets forth the
role of the Audit Committee with respect to this Policy), the Compensation Committee is authorized to interpret and construe this Policy
and to make all determinations necessary, appropriate, or advisable for the administration of this Policy. Any determinations by the
Audit Committee or the Compensation Committee, as applicable, shall be binding on all Executive Officers. The Compensation Committee
may, from time to time, recommend amendments to this Policy. Any amendments to this Policy must be approved by the Board. This Policy
shall be filed as an exhibit to the Company&rsquo;s Annual Report on Form 10-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. <B><U>Certain
Definitions</U></B>. For purposes of this Policy, the following terms shall have the meanings set forth below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) &ldquo;<B>Accounting
Restatement</B>&rdquo; means a restatement of any Company Financial Statements which is required as a result of, or necessitated by,
any material noncompliance by the Company with any financial reporting requirement under the federal securities laws, including any accounting
restatement that (i) corrects errors that are material to previously issued Company Financial Statements (commonly referred to as &ldquo;Big
R&rdquo; restatements), or (ii) corrects errors that are not material to previously issued Company Financial Statements, but would result
in a material misstatement if the errors were left uncorrected in the current report, or the error correction was recognized in the current
period (commonly referred to as &ldquo;little r&rdquo; restatements).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) &ldquo;<B>Accounting
Restatement Date</B>&rdquo; means the date on which the Company is required to prepare an Accounting Restatement, which shall be the
<U>earlier</U> of: (i) the date the Board concludes, or reasonably should have concluded, that the Company is required to prepare an
Accounting Restatement, and (ii) the date a court, regulator, or other legally authorized body directs the Company to prepare an Accounting
Restatement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-left: 0in; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Audit Committee</B>&rdquo; means the Audit Committee of the Board</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) &ldquo;<B>Company
Financial Statements</B>&rdquo; means any audited or unaudited financial statements of the Company included in any SEC Report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Compensation Committee</B>&rdquo; means the Compensation Committee of the Board.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Exchange Act</B>&rdquo; means the Securities and Exchange Act of 1934, as amended.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g) &ldquo;<B>Executive
Officer</B>&rdquo; means any person who is or has been designated by the Board as an &ldquo;officer&rdquo; for purposes of Rule 16a-1(f)
under the Exchange Act, who hold such position at the time the Incentive-Based Compensation at issue under this Policy was granted, earned,
or vested.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h) &ldquo;<B>Financial
Reporting Measures</B>&rdquo; means measures that are determined and presented in accordance with the accounting principles used in preparing
the Company Financial Statements, as well as any measures derived wholly or in part from such measures, including non-GAAP financial
measures, regardless of whether such measures were presented in the Company Financial Statements or an SEC Report. Financial Reporting
Measures include, without limitation, the Company&rsquo;s stock price and total stockholder return.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) &ldquo;<B>Incentive-Based
Compensation</B>&rdquo; means any cash or equity bonus or other compensation that is granted, earned, or vested based wholly or in part
on the attainment of a Financial Reporting Measure, including, but not limited to, annual cash bonuses, short- and long-term cash incentive
awards, stock options, restricted stock, restricted stock units, stock appreciation rights or performance shares, and the proceeds from
the sale of shares acquired through an incentive plan that were granted or vested solely or in part on satisfying a Financial Reporting
Measure performance goal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j) &ldquo;<B>Received</B>&rdquo;
means received in the fiscal period during which a Financial Reporting Measure is attained, even if the Incentive-Based Compensation
payment or award (or the vesting of such award) occurs after the end of that period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -36.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k) &ldquo;<B>Recovery
Period</B>&rdquo; means the three completed fiscal years immediately preceding the Accounting Restatement Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -36.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l) &ldquo;<B>Restated
Financial Statements</B>&rdquo; means Company Financial Statements as restated as a result of an Accounting Restatement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>SEC</B>&rdquo; means the Securities and Exchange Commission.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n) &ldquo;<B>SEC
Report</B>&rdquo; means an Annual Report on Form 10-K, Quarterly Report on Form 10-Q or any other report containing Company Financial
Statements that is filed by the Company with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 41.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">2. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Accounting
Restatement: Provisions Applicable to Executive Officers</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In each instance where <U>all</U> three of the following factors exist:</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) an
Accounting Restatement has occurred;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) Incentive-Based
Compensation was Received by an Executive Officer during the Recovery Period after beginning service as an Executive Officer; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) the
Audit Committee, in its sole discretion exercised in good faith, determines that the amount or reported value of that Incentive-Based
Compensation that was paid to or Received by such Executive Officer during the Recovery Period exceeds the amount or reported value of
the Incentive-Based Compensation that would have been Received by such Executive Officer if such amount or value had been determined
on the basis of the Restated Financial Statements (such excess amount or value, the &ldquo;<B>Excess Incentive-Based Compensation</B>&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Then</U>:
the Company shall, in accordance with <U>Section 4(b)</U>, seek to recoup or recover the amount or value of such Excess Incentive-Based
Compensation from the Executive Officer. The Company is entitled to recoup or recover Excess Incentive-Based Compensation pursuant to
the terms of this Policy regardless of any fault of the Executive Officer for the accounting error(s) necessitating the Accounting Restatement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) If
the Audit Committee cannot determine the amount of Excess Incentive-Based Compensation Received by the Executive Officer directly from
the information in the Accounting Restatement, then it shall make its determination based on a reasonable estimate of the effect of the
Accounting Restatement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">3.</FONT>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><B>No Indemnity or Insurance Reimbursement</B></U><B>.</B></FONT></P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-decoration: none">The
Company shall not insure or indemnify any Executive Officer against the loss of any Incentive-Based Compensation subject to recoupment
or forfeiture hereunder. The Company shall not pay or reimburse any Executive Officer for premiums paid toward an insurance policy to
fund potential recovery obligations.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">4.</FONT>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><B>General Provisions</B></U><B>.</B></FONT></P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <U>Calculation
of Erroneously Awarded Incentive-Based Compensation</U>. Any Excess Incentive-Based Compensation that the Company is entitled to recoup
or recover pursuant to the terms of this Policy shall be calculated without regard to any taxes paid by the Executive Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) <U>Recoupment
Methods</U>. The Compensation Committee shall determine, in its sole discretion, the method for recouping Excess Incentive-Based Compensation
hereunder, which may include, without limitation: (i) requiring reimbursement of cash Incentive-Based Compensation previously paid; (ii)
seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer, or other disposition of any equity incentive
awards; (iii) cancelling or rescinding some or all outstanding vested or unvested equity incentive awards; (iv) offsetting the recouped
amount from any compensation otherwise owed by the Company to the Executive Officer (including compensation that is not incentive-based);
(v) cancelling or setting-off against planned future grants of cash incentive awards or equity incentive awards; (vi) any other method
authorized by any agreement between the Company and a particular Executive Officer; or (vii) taking any other remedial and recovery action
permitted by law. The Company must seek to recover or recoup Excess Incentive-Based Compensation except to the extent that the Compensation
Committee or a majority of the independent members of the Board determines that recovery would be impracticable and the conditions for
such determination set forth in the Rules are satisfied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) <U>Rights
and Remedies</U>. The Board intends that this Policy shall be applied to the fullest extent of the law. The Board may require that any
employment agreement, equity award agreement, or similar agreement entered into on or after the Effective Date shall, as a condition
to the grant of any benefit thereunder, require an Executive Officer to agree to abide by the terms of this Policy. Any right of recoupment
under this Policy is in addition to, and not in lieu of, any other remedies or rights of recoupment that may be available to the Company
pursuant to the terms of any similar policy in any employment agreement, equity award agreement, or similar agreement and any other legal
remedies available to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) <U>Binding
Agreement</U>. This Policy shall be binding and enforceable against all Executive Officers and their respective beneficiaries, heirs,
executors, administrators or other legal representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>bmra-20250531.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWauA6bP9z5Z8qekhvWB4benarywpAKXgGSvYwQh2oREI -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:BMRA="http://biomerica.com/20250531" elementFormDefault="qualified" targetNamespace="http://biomerica.com/20250531">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://biomerica.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="bmra-20250531_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="bmra-20250531_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
    <element id="BMRA_NoInsiderTradingFlag" name="NoInsiderTradingFlag" nillable="true" xbrli:periodType="duration" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_OperatingLeaseRightOfUseAssetAccumulatedAmortization" name="OperatingLeaseRightOfUseAssetAccumulatedAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_CashPaidDuringYearForAbstract" name="CashPaidDuringYearForAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_LiquidityPolicyTextBlock" name="LiquidityPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_WorkingCapital" name="WorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" name="ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_SaleOfStockExpenses" name="SaleOfStockExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_DistributorOneMember" name="DistributorOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_TwoDistributorsMember" name="TwoDistributorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_FourDistributorMember" name="FourDistributorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_DistributorsInAsiaMember" name="DistributorsInAsiaMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_OneVendorMember" name="OneVendorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_ConcentrationRiskGeographicPolicyPolicyTextBlock" name="ConcentrationRiskGeographicPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_PrepaidExpensesAndOtherPolicyTextBlock" name="PrepaidExpensesAndOtherPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_PurchasedTechnologyRightsMember" name="PurchasedTechnologyRightsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_PolishDistributorMember" name="PolishDistributorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_FiniteLivedPatentsAccumulatedAmortization" name="FiniteLivedPatentsAccumulatedAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_TwoVendorMember" name="TwoVendorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_TwoThousandSeventeenPlanMember" name="TwoThousandSeventeenPlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_TwoThousandTwentyPlanMember" name="TwoThousandTwentyPlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_TwoThousandTwentyThreePlanMember" name="TwoThousandTwentyThreePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_TwoThousandTwentyFourPlanMember" name="TwoThousandTwentyFourPlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_DefferedTaxAssetsStockOptions" name="DefferedTaxAssetsStockOptions" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_DeferredTaxAssetsCapitalizedCosts" name="DeferredTaxAssetsCapitalizedCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet" name="DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_DeferredTaxAssetsAccumulatedDepreciationAndAmortization" name="DeferredTaxAssetsAccumulatedDepreciationAndAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_PercentageOfTotalRevenues" name="PercentageOfTotalRevenues" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_BuildingInIrvineCaliforniaMember" name="BuildingInIrvineCaliforniaMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_ScheduleOfSupplementalLeaseInformationTableTextBlock" name="ScheduleOfSupplementalLeaseInformationTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_RoyaltyExpensePercentageOfSales" name="RoyaltyExpensePercentageOfSales" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_ATMOfferingMember" name="ATMOfferingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_MarketingAndDistributionRightsMember" name="MarketingAndDistributionRightsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_ShippingAndHandlingCostsPolicyTextBlock" name="ShippingAndHandlingCostsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_PaymentsOfDeferredOfferingCosts" name="PaymentsOfDeferredOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_DeferredOfferingCost" name="DeferredOfferingCost" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_ReverseStockSplitPolicyTextBlock" name="ReverseStockSplitPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_ATMAgreementMember" name="ATMAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_ClinicalLabMember" name="ClinicalLabMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_OverTheCounteMember" name="OverTheCounteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_ContractManufacturingMember" name="ContractManufacturingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_PhysiciansOfficeMember" name="PhysiciansOfficeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="BMRA_FurnitureAndFixturesLeaseholdImprovementsMember" name="FurnitureAndFixturesLeaseholdImprovementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>bmra-20250531_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityListingParValuePerShare" xlink:label="dei_EntityListingParValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityListingParValuePerShare" xlink:to="dei_EntityListingParValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityListingParValuePerShare_lbl" xml:lang="en-US">Entity Listing, Par Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20250531.xsd#BMRA_NoInsiderTradingFlag" xlink:label="BMRA_NoInsiderTradingFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_NoInsiderTradingFlag" xlink:to="BMRA_NoInsiderTradingFlag_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_NoInsiderTradingFlag_doc" xml:lang="en-US">No insider trading flag.</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20250531.xsd#BMRA_OperatingLeaseRightOfUseAssetAccumulatedAmortization" xlink:label="BMRA_OperatingLeaseRightOfUseAssetAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_OperatingLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="BMRA_OperatingLeaseRightOfUseAssetAccumulatedAmortization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_OperatingLeaseRightOfUseAssetAccumulatedAmortization_doc" xml:lang="en-US">Accumulated amortization.</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20250531.xsd#BMRA_CashPaidDuringYearForAbstract" xlink:label="BMRA_CashPaidDuringYearForAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_CashPaidDuringYearForAbstract" xlink:to="BMRA_CashPaidDuringYearForAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_CashPaidDuringYearForAbstract_doc" xml:lang="en-US">Cash Paid During Year For [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20250531.xsd#BMRA_LiquidityPolicyTextBlock" xlink:label="BMRA_LiquidityPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_LiquidityPolicyTextBlock" xlink:to="BMRA_LiquidityPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_LiquidityPolicyTextBlock_doc" xml:lang="en-US">Liquidity [Policy Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20250531.xsd#BMRA_WorkingCapital" xlink:label="BMRA_WorkingCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_WorkingCapital" xlink:to="BMRA_WorkingCapital_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_WorkingCapital_doc" xml:lang="en-US">Working capital.</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20250531.xsd#BMRA_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" xlink:label="BMRA_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue" xlink:to="BMRA_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_ShelfRegistrationStatementMaximumAuthorizedCommonStockIssuanceValue_doc" xml:lang="en-US">Shelf registration statement maximum authorized common stock issuance value.</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20250531.xsd#BMRA_SaleOfStockExpenses" xlink:label="BMRA_SaleOfStockExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_SaleOfStockExpenses" xlink:to="BMRA_SaleOfStockExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_SaleOfStockExpenses_doc" xml:lang="en-US">Sale of stock expenses.</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20250531.xsd#BMRA_DistributorOneMember" xlink:label="BMRA_DistributorOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_DistributorOneMember" xlink:to="BMRA_DistributorOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_DistributorOneMember_doc" xml:lang="en-US">Distributor One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20250531.xsd#BMRA_TwoDistributorsMember" xlink:label="BMRA_TwoDistributorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_TwoDistributorsMember" xlink:to="BMRA_TwoDistributorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_TwoDistributorsMember_doc" xml:lang="en-US">Two Distributors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20250531.xsd#BMRA_FourDistributorMember" xlink:label="BMRA_FourDistributorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_FourDistributorMember" xlink:to="BMRA_FourDistributorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_FourDistributorMember_doc" xml:lang="en-US">Four Distributor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20250531.xsd#BMRA_DistributorsInAsiaMember" xlink:label="BMRA_DistributorsInAsiaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_DistributorsInAsiaMember" xlink:to="BMRA_DistributorsInAsiaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_DistributorsInAsiaMember_doc" xml:lang="en-US">Distributors in Asia [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20250531.xsd#BMRA_OneVendorMember" xlink:label="BMRA_OneVendorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_OneVendorMember" xlink:to="BMRA_OneVendorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_OneVendorMember_doc" xml:lang="en-US">One Vendor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20250531.xsd#BMRA_ConcentrationRiskGeographicPolicyPolicyTextBlock" xlink:label="BMRA_ConcentrationRiskGeographicPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_ConcentrationRiskGeographicPolicyPolicyTextBlock" xlink:to="BMRA_ConcentrationRiskGeographicPolicyPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_ConcentrationRiskGeographicPolicyPolicyTextBlock_doc" xml:lang="en-US">Concentration Risk Geographic Policy [Policy Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20250531.xsd#BMRA_PrepaidExpensesAndOtherPolicyTextBlock" xlink:label="BMRA_PrepaidExpensesAndOtherPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_PrepaidExpensesAndOtherPolicyTextBlock" xlink:to="BMRA_PrepaidExpensesAndOtherPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_PrepaidExpensesAndOtherPolicyTextBlock_doc" xml:lang="en-US">Prepaid Expenses And Other [Policy Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20250531.xsd#BMRA_PurchasedTechnologyRightsMember" xlink:label="BMRA_PurchasedTechnologyRightsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_PurchasedTechnologyRightsMember" xlink:to="BMRA_PurchasedTechnologyRightsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_PurchasedTechnologyRightsMember_doc" xml:lang="en-US">Purchased Technology Rights [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20250531.xsd#BMRA_PolishDistributorMember" xlink:label="BMRA_PolishDistributorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_PolishDistributorMember" xlink:to="BMRA_PolishDistributorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_PolishDistributorMember_doc" xml:lang="en-US">Polish Distributor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20250531.xsd#BMRA_FiniteLivedPatentsAccumulatedAmortization" xlink:label="BMRA_FiniteLivedPatentsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_FiniteLivedPatentsAccumulatedAmortization" xlink:to="BMRA_FiniteLivedPatentsAccumulatedAmortization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_FiniteLivedPatentsAccumulatedAmortization_doc" xml:lang="en-US">Finite lived patents accumulated amortization.</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20250531.xsd#BMRA_TwoVendorMember" xlink:label="BMRA_TwoVendorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_TwoVendorMember" xlink:to="BMRA_TwoVendorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_TwoVendorMember_doc" xml:lang="en-US">Two Vendor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20250531.xsd#BMRA_TwoThousandSeventeenPlanMember" xlink:label="BMRA_TwoThousandSeventeenPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_TwoThousandSeventeenPlanMember" xlink:to="BMRA_TwoThousandSeventeenPlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_TwoThousandSeventeenPlanMember_doc" xml:lang="en-US">2017 Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20250531.xsd#BMRA_TwoThousandTwentyPlanMember" xlink:label="BMRA_TwoThousandTwentyPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_TwoThousandTwentyPlanMember" xlink:to="BMRA_TwoThousandTwentyPlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_TwoThousandTwentyPlanMember_doc" xml:lang="en-US">2020 Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20250531.xsd#BMRA_TwoThousandTwentyThreePlanMember" xlink:label="BMRA_TwoThousandTwentyThreePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_TwoThousandTwentyThreePlanMember" xlink:to="BMRA_TwoThousandTwentyThreePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_TwoThousandTwentyThreePlanMember_doc" xml:lang="en-US">2023 Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20250531.xsd#BMRA_TwoThousandTwentyFourPlanMember" xlink:label="BMRA_TwoThousandTwentyFourPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_TwoThousandTwentyFourPlanMember" xlink:to="BMRA_TwoThousandTwentyFourPlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_TwoThousandTwentyFourPlanMember_doc" xml:lang="en-US">2024 Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20250531.xsd#BMRA_DefferedTaxAssetsStockOptions" xlink:label="BMRA_DefferedTaxAssetsStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_DefferedTaxAssetsStockOptions" xlink:to="BMRA_DefferedTaxAssetsStockOptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_DefferedTaxAssetsStockOptions_doc" xml:lang="en-US">Deffered tax assets stock options.</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20250531.xsd#BMRA_DeferredTaxAssetsCapitalizedCosts" xlink:label="BMRA_DeferredTaxAssetsCapitalizedCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_DeferredTaxAssetsCapitalizedCosts" xlink:to="BMRA_DeferredTaxAssetsCapitalizedCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_DeferredTaxAssetsCapitalizedCosts_doc" xml:lang="en-US">Deferred tax assets capitalized costs.</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20250531.xsd#BMRA_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet" xlink:label="BMRA_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet" xlink:to="BMRA_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_DeferredTaxAssetsLossesOfForeignSubsidiariesOtherNet_doc" xml:lang="en-US">Deferred tax assets losses of foreign subsidiaries other net.</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20250531.xsd#BMRA_DeferredTaxAssetsAccumulatedDepreciationAndAmortization" xlink:label="BMRA_DeferredTaxAssetsAccumulatedDepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_DeferredTaxAssetsAccumulatedDepreciationAndAmortization" xlink:to="BMRA_DeferredTaxAssetsAccumulatedDepreciationAndAmortization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_DeferredTaxAssetsAccumulatedDepreciationAndAmortization_doc" xml:lang="en-US">Deferred Tax Assets Accumulated Depreciation and Amortization.</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20250531.xsd#BMRA_PercentageOfTotalRevenues" xlink:label="BMRA_PercentageOfTotalRevenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_PercentageOfTotalRevenues" xlink:to="BMRA_PercentageOfTotalRevenues_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_PercentageOfTotalRevenues_doc" xml:lang="en-US">Percentage of total revenues.</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20250531.xsd#BMRA_BuildingInIrvineCaliforniaMember" xlink:label="BMRA_BuildingInIrvineCaliforniaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_BuildingInIrvineCaliforniaMember" xlink:to="BMRA_BuildingInIrvineCaliforniaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_BuildingInIrvineCaliforniaMember_doc" xml:lang="en-US">Building in Irvine California [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20250531.xsd#BMRA_ScheduleOfSupplementalLeaseInformationTableTextBlock" xlink:label="BMRA_ScheduleOfSupplementalLeaseInformationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_ScheduleOfSupplementalLeaseInformationTableTextBlock" xlink:to="BMRA_ScheduleOfSupplementalLeaseInformationTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_ScheduleOfSupplementalLeaseInformationTableTextBlock_doc" xml:lang="en-US">Schedule of Supplemental Lease Information [Table Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20250531.xsd#BMRA_RoyaltyExpensePercentageOfSales" xlink:label="BMRA_RoyaltyExpensePercentageOfSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_RoyaltyExpensePercentageOfSales" xlink:to="BMRA_RoyaltyExpensePercentageOfSales_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_RoyaltyExpensePercentageOfSales_doc" xml:lang="en-US">Royalty expense percentage of sales.</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20250531.xsd#BMRA_ATMOfferingMember" xlink:label="BMRA_ATMOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_ATMOfferingMember" xlink:to="BMRA_ATMOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_ATMOfferingMember_doc" xml:lang="en-US">ATM Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20250531.xsd#BMRA_MarketingAndDistributionRightsMember" xlink:label="BMRA_MarketingAndDistributionRightsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_MarketingAndDistributionRightsMember" xlink:to="BMRA_MarketingAndDistributionRightsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_MarketingAndDistributionRightsMember_doc" xml:lang="en-US">Marketing and Distribution Rights [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20250531.xsd#BMRA_ShippingAndHandlingCostsPolicyTextBlock" xlink:label="BMRA_ShippingAndHandlingCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_ShippingAndHandlingCostsPolicyTextBlock" xlink:to="BMRA_ShippingAndHandlingCostsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_ShippingAndHandlingCostsPolicyTextBlock_doc" xml:lang="en-US">Shipping And Handling Costs [Policy Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20250531.xsd#BMRA_PaymentsOfDeferredOfferingCosts" xlink:label="BMRA_PaymentsOfDeferredOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_PaymentsOfDeferredOfferingCosts" xlink:to="BMRA_PaymentsOfDeferredOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_PaymentsOfDeferredOfferingCosts_doc" xml:lang="en-US">Payments of deferred offering costs.</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20250531.xsd#BMRA_DeferredOfferingCost" xlink:label="BMRA_DeferredOfferingCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_DeferredOfferingCost" xlink:to="BMRA_DeferredOfferingCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_DeferredOfferingCost_doc" xml:lang="en-US">Deferred offering cost</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20250531.xsd#BMRA_ReverseStockSplitPolicyTextBlock" xlink:label="BMRA_ReverseStockSplitPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_ReverseStockSplitPolicyTextBlock" xlink:to="BMRA_ReverseStockSplitPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_ReverseStockSplitPolicyTextBlock_doc" xml:lang="en-US">Reverse Stock Split [Policy Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20250531.xsd#BMRA_ATMAgreementMember" xlink:label="BMRA_ATMAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_ATMAgreementMember" xlink:to="BMRA_ATMAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_ATMAgreementMember_doc" xml:lang="en-US">ATM Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20250531.xsd#BMRA_ClinicalLabMember" xlink:label="BMRA_ClinicalLabMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_ClinicalLabMember" xlink:to="BMRA_ClinicalLabMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_ClinicalLabMember_doc" xml:lang="en-US">Clinical Lab [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20250531.xsd#BMRA_OverTheCounteMember" xlink:label="BMRA_OverTheCounteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_OverTheCounteMember" xlink:to="BMRA_OverTheCounteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_OverTheCounteMember_doc" xml:lang="en-US">Over The Counter [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20250531.xsd#BMRA_ContractManufacturingMember" xlink:label="BMRA_ContractManufacturingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_ContractManufacturingMember" xlink:to="BMRA_ContractManufacturingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_ContractManufacturingMember_doc" xml:lang="en-US">Contract Manufacturing [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20250531.xsd#BMRA_PhysiciansOfficeMember" xlink:label="BMRA_PhysiciansOfficeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_PhysiciansOfficeMember" xlink:to="BMRA_PhysiciansOfficeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_PhysiciansOfficeMember_doc" xml:lang="en-US">Physicians Office [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bmra-20250531.xsd#BMRA_FurnitureAndFixturesLeaseholdImprovementsMember" xlink:label="BMRA_FurnitureAndFixturesLeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BMRA_FurnitureAndFixturesLeaseholdImprovementsMember" xlink:to="BMRA_FurnitureAndFixturesLeaseholdImprovementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="BMRA_FurnitureAndFixturesLeaseholdImprovementsMember_doc" xml:lang="en-US">Furniture and Fixtures Leasehold Improvements [Member]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>bmra-20250531_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="bmra-20250531.xsd#Cover" roleURI="http://biomerica.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://biomerica.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityListingParValuePerShare" xlink:label="loc_deiEntityListingParValuePerShare" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityListingParValuePerShare" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2025</div></th>
<th class="th"><div>Sep. 26, 2025</div></th>
<th class="th"><div>Nov. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K/A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">This
Amendment No. 1 on Form 10-K/A (this &#8220;Amendment No. 1&#8221;) amends the Annual Report on Form 10-K for the fiscal year ended May
31, 2025 (the &#8220;2025 Annual Report&#8221;), originally filed by Biomerica, Inc. with the Securities and Exchange Commission (the
&#8220;SEC&#8221;) on August 29, 2025. References throughout this Amendment No. 1 to &#8220;Biomerica, Inc.&#8221;, &#8220;Biomerica&#8221;,
&#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;, or the &#8220;Company&#8221; refer to Biomerica, Inc. and its subsidiaries, taken
as a whole, unless the context otherwise indicates.&#160;We
are filing this Amendment No. 1 pursuant to General Instruction G(3) of Form 10-K, as we do not intend to file a definitive proxy statement
for our 2025 Annual Meeting of stockholders (the &#8220;Annual Meeting&#8221;) within 120 days of the end of our fiscal year ended May
31, 2025. Accordingly, this Amendment No. 1 is being filed solely to:

&#160;



    &#160;
    &#9679;
    amend
    and restate Part III, Items 10 (Directors, Executive Officers and Corporate Governance), 11 (Executive Compensation), 12 (Security
    Ownership of Certain Beneficial Owners and Management Related Stockholder Matters), 13 (Certain Relationships and Related Transactions,
    and Director Independence) and 14 (Principal Accountant Fees and Services) of our 2025 Annual Report, in their entirety as set forth
    herein; and

    &#160;
    &#160;
    &#160;

    &#160;
    &#9679;
    file
    new certifications of our principal executive officer and principal financial officer as exhibits to this Amendment No. 1 under Item
    15 of Part IV hereof pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).

&#160;

Because
no financial statements have been included in this Amendment No. 1, and because this Amendment No. 1 does not contain or amend any disclosure
with respect to paragraphs 3, 4 and 5 of Items 307 and 308 of Regulation S-K, the corresponding certifications have been omitted. We
are not including the certifications under Section 906 of the Sarbanes-Oxley Act of 2002, as no financial statements are being filed
with this Amendment No. 1.

&#160;

Except
as set forth above, no other Items of our 2025 Annual Report have been amended or revised in this Amendment No. 1, and all such other
Items shall be as set forth in such 2025 Annual Report. Accordingly, this Amendment No. 1 should be read in conjunction with the 2025
Annual Report and our other filings with the SEC. Certain capitalized terms used and not otherwise defined in this Amendment No. 1 have
the meanings given to them in the 2025 Annual Report.

&#160;

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--05-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOMERICA,
INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000073290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-2645573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">17571
    Von Karman Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Irvine<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">645-2111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, par value $0.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BMRA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,869,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingParValuePerShare', window );">Entity Listing, Par Value Per Share</a></td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The par value per share of security quoted in same currency as Trading currency. Example: '0.01'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>36</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="form10-ka.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biomerica.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>bmra-20250531.xsd</File>
    <File>bmra-20250531_lab.xml</File>
    <File>bmra-20250531_pre.xml</File>
    <File doctype="10-K/A" isDefinitelyFs="true" isOnlyDei="true" isUsgaap="true" original="form10-ka.htm">form10-ka.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="36">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form10-ka.htm": {
   "nsprefix": "BMRA",
   "nsuri": "http://biomerica.com/20250531",
   "dts": {
    "schema": {
     "local": [
      "bmra-20250531.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "bmra-20250531_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bmra-20250531_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "form10-ka.htm"
     ]
    }
   },
   "keyStandard": 36,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 62,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 36
   },
   "report": {
    "R1": {
     "role": "http://biomerica.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2024-06-01to2025-05-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-ka.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-06-01to2025-05-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-ka.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14",
      "r16"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://biomerica.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001493152-25-015785-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-25-015785-xbrl.zip
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M9P%=$*#TF#.>VFIY"Y216J#+-*?YBUQ.]V6W61!NR9PI\<4&9*YDHGL]"!8
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M-T0'FJ]H[-&'!=XPLUW&BJAR]Q+:MIK<3$8>JJ6=S&_4R^I%O0PWK1:1-UQ
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M1F41Q8 XUC0@=J7?\VC[AUZH5[*^-[(^CS:(CF"W$IOSEO%X.:^R+(B  GU
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MY-(S^&U\:O;&(G^%D;WI^ M02P,$%     @ #8HZ6[<O'4/B P  7AL   H
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M;;0OSTLU?S]6OC#+WZO] U!+ P04    "  -BCI;CEW4_GL3  "19P  "0
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M9:6;&RG%<2Z+I"6$-.7A( $<+.8Z>]2&WT@HK19D"?C@).!2_U[IQ/H 9W#
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M[/;%L^Y5"@I<U2X#YBL.@CW'P(0!0>;W7+TUOWNQ?S!J-)[8"0+^@&E%#O5
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MV>'!<_L3[CYWMP^.KT[_8F]N_[HX^^59HO)RC^V^*$IV*S-AV*6X8S<JX_G
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M&$?(=P/Z^@2K#DP%G@J\39$_YAP)&WR&7U;F#.%ABA'4@90FV(QN^5AS,(O
M/P&W)X>?_1Y,=0HF_R*/?VZ6\'SJ)>[@7\,A^U6*--YCUWPL]N&C[RL!Q( 7
M]MD592[-'D[.)UN&0U>V=G!Z_J=?36M*/^*41DH#M>IKQRF/WK%=6*\!TL7
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MK_J] +"\.V8+CKLJ^H@OS^X]1/BE&O&?[@A@-Y-]O[OSTUK5M;MP)]!WQ#.
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MTTK4H;S57&ICV\!3!9=4B0T#A5Q+$<./XEOQP4;<[YF<#<:O+-ZP<VOJR:D
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M,,.R&/O M?["04E]6VY%#_T!O-_OU9:#;Z22\=FJTR*VD8KM>&)[/ 4F,DH
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M4>,$S^)? 0FK;^2*@[G[X2_4S^'9U6\2E:GHK;E7 P*J"#)#87=0*N1G[WT
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MP\KU'E*^#&<<)D"EW47S:#[5+VJ9]O5$K"8@4%?:PWRK8R3& CT=M2901KF
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MA#XS3,I?81CBX/AVFEYX/M5%<CPQ[1EHNF1=]54?H2FC,D]IE?VI)PUB"Z)
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MOUA9L%[T]9A2.1+>GD#(H$VPT7P8AU2](^.*0VXGC*Q+'2?H0"W 8:"YHSP
M:T$M?6H9/:F'$:*B<_GCY C0L*B,VJGR^82RN&,QYX*N0@8ZV=R;-'S#NN5P
MB(9R_E!R";PXF)I*4DIR+<KH:Q'9*Y151#ONF&=K4O6-.!@%G=MI*TS.1"?9
MSE\(33Z3"2L@S.14)&"<ZV*(M(7Y*Y:OK,""'!'F339 W8R)OD37\"L12YB$
M<D%>1V"2<$69#PS$EM'B:*+@2*061RQ@.W 1R*E%*86P*<Y.QL^W@Y]O)MXO
M-FLTZB])H4S61Q/E?J%Z)D3@+58]8QQC2X/^T@!_ZI _8CSWPO8X?5-;H&\F
M*7G^6I8$;CG]4HOKEXFJ;DS!#.5:T!TA#9T+5O W (#Y4:XD'1F\3A=$X)+1
M AE!,& 5L"[D*!B:HLZCNY<@POG#F#,&UPK'K"(RHL9M^//L@GO:G$Q T>3D
MHG*)G<!E0UZF4"$GW@/.XJE@B\:/WHCR?6AD$92_+Y?<;M15EBB]V]+=OO[W
MJLI /1]OZ1:L9.G@C),L.&.-P1F'67!&%IRQ/6+LBBV$JAR=UFR=-:X;\#^M
M>F8G?.H2=,K1.R<+8'@ RB"^$Y<254?4#LX=D?2A4MDB@: 40"#L#C2JX<3&
M!7E">11T4^OJH$"$Y:P@1Y82"!W=<O6>%TI>-T5$P,B8N$PEO86EI5#5,Y%S
M%W50AX$)S:OYLIT;A5?$Q$K+:)^#Q.5GGJO$1(6A9N@[7Z!SQ4="4/;K8 HA
M/")1HJ %"KO3IR@)TH9NX%56/2Q4E1AWJ3O?N3>!:Y730Y+OA&"59Z<$Z71"
ML(((*;8V4M!/)Y^Z0;[[6TP$72C1:BC1/D2%0S=\2/O(L7V\%T1JN<H:E4AK
MAI04OX6U7U4D8PF;J1)ZT:B=-6[:'YO7K-VY^53O?+K)6/)3LV1AV*54FY#R
MB^P!C:<6!O-X+,2N/)7DC,>KRUU/&)BYZT6R'8 7*M>O$:JEXZOL03P,EC+P
MQ_?+\?BV"4"! =P -6UW1/4E?(T=1)^15-O3H]T25'JQ<'')R,ELEVN.C2Q.
M3M)%2Q#&0<*5@XP;U5^3_S"D076"X$:<!AAFZ0QU"XL,X1,5>.:J6@QD1,8G
M?KF).23SL:N-;4!I4")#(,\ZF !_U0TRB_0,IS<=H_;<"VS$LH2+O%@5QL@*
MX-]PM'.X90?NU)!7:32=<:PK)$GJT(7=&Q !TC,66"*+'RC]GHC2PG_%>3Z&
MK<U HP^L2#JS@#+E)H0G3;&Y"!-]QA8VPY9OKBX:K-EB-\WV'PP+\K6;'SYV
M,L;\Q(PYS6>J/)(@5<$8Z"$UW.\N5AI2-E/)?\-I5[[I+L=Z,S35"<O:3%6*
M\1V;-)@,4-5B'C0*K$T BV15?0:ZZ0'\$?X"P,0!8^&\7LS,*<+B^]'EJ=C3
M'I8NLK&ZE"9'4QK G&4V)(HGA6,&!>6#&#:,SW50-"5':2 DQM+ZXIZ(Q5.I
MHCY"Z!4.[)C:XD:<A_"QS/J3GC'KUC9O0]F$?B4CL7YELM5\$Z]RIV<>LB<X
ML\!)WQGOS_TC1D$Q\CR)ZH?"\<YN\'"]>VV\SYCKUK@RD06YO1'O@X)+,0J&
MW<<3AQJS</#XT>F4[AM4MXO'X@9A%>B-PG.+N3ET8OF/B>U.'2FN 5NFVEW:
MF'N@_<:JPV$[)&%WP'_:;&C:78 BQ,'#GG;B1,@=ILXL7$U(QGP(3Y"40(D(
M<Z$ CVCHBA9< \3U7!Y9;@]9C)#+/3YQPRNG< /].R?A3IIC<FK&G)R&N* [
M!1;L8R.'C!!+G/FR8#0J0?-S;>.UT@BKHM*G']Q!OP5099SPJ3AA0P:P1$/N
M,^;W],PO+6%+"@\)HIL;X45)D4/SB371S'@_\2=\L&-Q60MD*5$Z4=3T%2\*
ML. GNV>0W.CG+2X&+9JWCV9>T)\U*B6 M4)5U%68&T>3)E7:FN*.JF;;/)Y4
M3I(^[J+,.T7VZ RY)\KE18*\)+"Q;#G!:"G8#$-+!M*V+1/+1&9G3@TT0JLV
MF;J] W'=A LLA ?.2;O+1)8BEJ894=$2@_)2OV1"-B9H+!]Z(%EKZJC[ZI;"
MX  K>!^)T:F &V ;J]^)^P.(U-_RB8UYIZC#&+!Q/2(ZO"$T6395&<(=3N\)
MQ*B$K0-9VB$>-9<+62M0L(=G+K<,.ZS**/.U/SX&J;E^[EEPL>2TL''?S\KK
M<M/@N%P1Q[84I;&?H+2<C'O1!(G1=*(CEN[:EMZE0(SOJ&5XMBHRZNN%>E_4
M2!7&I%BX=78[;J"RE&QSH 5M#K*[[ZDS%?S+(;$F_;4HS2LB=5WU3S@ZI\IH
M6_?#@?O8^!J+ JL8)/E/\9$?C:2.?5 >70N.-^6J^O&^4?MYF#TDL0:J(X]&
M88JE2,^F8'XZA9&4*&&\SVOM<%%VS-*@B#V9.SR03;:H<!+F4 NC;L^>^-'L
MP#-E4>.N*/<:D1<4GML<3?X8YQM=*,(&;%K#D3%FSYQ;;A;"M5TK63J$JUC(
M8KC6&,-UE,5P93%<VW.-KSJ&JW'1;/WG4Z/5T=J-.A;H9,7#??T5NVF 8-7)
M.HH^C3#5YN38UL1>R*O<C\VN]3R5 ^>F5 [,A5O%R,PPERRJ(Q Z[BS1=I)Z
M!Q0+OU)U%3138NH'=@'NF:"?D:KHAX=C#,$ 2ZI0O)2?-2A2 ^\L&'YD3)2F
M*'32P"CI2N$&H!<Z*]HH@Z]\ZP+0(!:FIS%"W2-T"N07'8JU ;GHL8E'T)E8
MXDO2+M5R0"W8G(DB(LLGSV2TOFZ.T[B\OKCZVFCD-!4_FJ,NQE?GY\UZXX9]
M;)Q]:+8^9(SG21C/%ZZ1C0,M,'K?GE!H"4:G"-4C6KI5I3[.)57NAXJ12H;T
MBMF1'N6VHYJ7"[.;*/-$%ALXSW"V@5NXX;0:P\("H:)90FC\"5K:C#ZU!=*E
MM_Q.AIUZ:!>" :5)S[T#82@GI")?,50\=3"U^NZK7+13&+>&(*!H:,(+A:WF
MA)%HA+R)WA\,7.Z))3E<K81"?^;>(1,7%]8[91H<4PRHL!#ZN)0@^^PWXTQK
MYTS-5KMYUKC1.C>U,^! [/KJHEG_FC&B)V)$PD"B.JJ#?!)8BIJR84['$0UE
M1*LNO_.79!X4V*Z;_ID*#A.:4*@.\;RTI$7-1:K)DTRPED?_COOF:8K5\2W%
MX;,_<>RQ[?&YD@:&!-Z3P)OZ'8P;!)%+;S%Q&DWXR-$$[<IN+2JA+Y3#!Y--
MW3S[PH-60MA[82Q[Y A_>#@89B"YKUIG+EP.T\\/@&$#!NB.0(P[P!!20NN$
M]Z;*'Q&.Z,>^,Q%4"]]4^M:I^!O*> 0(1T97U)M(WAF1\IZZ/Z*F'D$M4@,$
MW$0&,)8@;^7<1S<&"IAT33G$JXF$PNN9(YV\5D.SG&]?2U^9?((%O5!NIHBD
MQ@]:'RN>Y(NJ:BC*G2K1]8:DY:P,TJ(%+;6,%=OB8CTL0&Y%=\/7M5\1B;:7
M+=Z;I[\T8F[#4'#\PD!ZWQT1Z9V*I4G(.2B2H(*K")@?5JK71)B@< __0ZJM
M*AU#C%OP&24F"^9.I39[4G&?Z+,#^.=!N!I'U,\Y,DS;M2>C&?%WX7]4<GGD
M50T+K,(UJ&1U%8R)@4-=3*GRF1!5-Q5\*)T%$=N.@!(;7Q5Z=?WX5'QA.D$)
M70L%EZ844C7"W7NIN&NX0 YND>H?)SS'%&&+S-WWO5JV%;]:D]IJAHL%A7K1
M#7@?>Q"$A0*\B$4$&O5J WKQ%X'?]\G=[#N#(L&FV'6SWW?0>950@A?[:M+.
MB>N4,L,&CC[%>+A0<V.B'DN6@1T;KDQHR+.KJ;-X*T@6$(DC5"0W0D&H'>%5
MKN#R76/RC+BBPC7O@Z*D.Q;^"1!A7 2FN)$/'Q: US-V/K;(]2^2TG0/D:-"
M6?3$BE)CBIO;3#_*7>*/JPX)H\&,_F][^K="H>R[CYJ=QJ56+.99X\]&_5.G
M^;G!PC=9IMQLQ.2E<*^%<<^NSEFK=MDX"^V--(*MT>R^]O4^.Z&B:6EGO"=2
MD>&BK(B8L)10.LFSN1 F(M'-X1)W"?>[%#'Z/*52NB8K$XE;'<NY4#JU[<5K
MAE-C A4#A][,_GS:GBOS[21D,LHNZ!TJ35( @9Z+M=D6:MB$BQ*16!,O6DDL
MDIV(0L3 [DWOZ=(4RE?)23SXL8L8*X;[39>)_[.6L' 2 =R1[G#9SM3A(*19
M>59SR>&0BPA\('JYLG.M7"THB;JC8LJHT'S7MJ889;=/J?)XDXK*-[0DS):Q
MHN&"A/94E#^C,['K'+D.NQN)U,T8[O80UQ>NP>D2QU&6AY0;Q1?R-#I]5%L.
MU2L'O7OHRPPY_\CK)[-YD<L.*968:DT$\;]!EWM-=;D/NR))B9OK:"=\DWZ-
MC72V>[7P[I!IQ'H?42U4%L_6 DPX?$ YR))CX6UC!!G0BK7)6-N,X6S)"441
MD*Z)C.5L*7D!RR%!*'J;RXRI'MH',&B FW[>1H+X(<6[]*-?,['FZW"$[H.^
M32[6B/4;6(DF?*U^;PD];;B@J*R . (), I?R@F$LZCX Z.9TF2EFD.*H V;
M>M0+:SN:81R#Q%D9T>'&\R/\W 8$5\BF7>"R6.Q"%N#MV8ZJ\8/,3& N24QK
MA^<'N<^="D=*&D;1:^&!7(:F"I'YH%/%U -B\R+-,'54+?46H9A?\P[%0_DV
M"9:B)Y#30[^P2+;@6!I2V8&P@@3K36&IEL^>94Y&1"8.Q4:/Q[8EPH)C(JK
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ME3QK^$]^UZTI#J*FIZ:>-*W? $!F'V(*MYH2BY%@"0+*KJ?@834_]8]Z2/0
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M=PYN<;ESXMPIR0$3GJB*F6URO[UQ2EY5K-QK.+$*1DJB$I57):25BVE0<B,
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M;>J*W;YA#\$B_%UWK "=+P%[\G:29XNS=UWG]?MK+-I)?]NNQLUK6OK$D,$
M.\E#99%6!\@7;=#X$]V_';1Y?]1OJ;HC^RS,", @MF<[UX>>2U%\]K.J9_M
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M-K\$D6SNB*1(; W'Z+%3,NZ/#(OM'RTC-"V\JQ\BW"U"Z4/&20N-O;?\U2(
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M.2TQ+FAT;5!+ 0(4 Q0    (  V*.EO9V)*KZP,  / 8   *
M  "  =@_  !E>#,Q+3,N:'1M4$L! A0#%     @ #8HZ6[<O'4/B P  7AL
M  H              ( !ZT,  &5X,S$M-"YH=&U02P$"% ,4    "  -BCI;
MCEW4_GL3  "19P  "0              @ 'U1P  97@T+3(N:'1M4$L! A0#
M%     @ #8HZ6Y#@[:@+$@  WVT   H              ( !EUL  &5X.3<M
M,2YH=&U02P$"% ,4    "  -BCI;'"B10XV!  #A$04 #0
I@ '*;0  9F]R;3$P+6MA+FAT;5!+!08     "0 ) !<"  ""[P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>form10-ka_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:BMRA="http://biomerica.com/20250531"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="bmra-20250531.xsd" xlink:type="simple"/>
    <context id="From2024-06-01to2025-05-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2025-05-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-11-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
        </entity>
        <period>
            <instant>2024-11-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000073290</identifier>
        </entity>
        <period>
            <instant>2025-09-26</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Segment">
        <measure>BMRA:Segment</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2024-06-01to2025-05-31" id="Fact000003">true</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2024-06-01to2025-05-31" id="Fact000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2024-06-01to2025-05-31" id="Fact000005">0000073290</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2024-06-01to2025-05-31" id="Fact000013">10-K/A</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2024-06-01to2025-05-31" id="Fact000014">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2024-06-01to2025-05-31" id="Fact000015">2025-05-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2024-06-01to2025-05-31" id="Fact000016">--05-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2024-06-01to2025-05-31" id="Fact000017">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2024-06-01to2025-05-31" id="Fact000018">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2024-06-01to2025-05-31" id="Fact000019">001-37863</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2024-06-01to2025-05-31" id="Fact000020">BIOMERICA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2024-06-01to2025-05-31" id="Fact000021">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2024-06-01to2025-05-31" id="Fact000022">95-2645573</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2024-06-01to2025-05-31" id="Fact000023">17571     Von Karman Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2024-06-01to2025-05-31" id="Fact000024">Irvine</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2024-06-01to2025-05-31" id="Fact000025">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2024-06-01to2025-05-31" id="Fact000026">92614</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2024-06-01to2025-05-31" id="Fact000027">949</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2024-06-01to2025-05-31" id="Fact000028">645-2111</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2024-06-01to2025-05-31" id="Fact000029">Common     Stock, par value $0.08</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2024-06-01to2025-05-31" id="Fact000030">BMRA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2024-06-01to2025-05-31" id="Fact000031">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2024-06-01to2025-05-31" id="Fact000032">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2024-06-01to2025-05-31" id="Fact000033">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2024-06-01to2025-05-31" id="Fact000034">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2024-06-01to2025-05-31" id="Fact000035">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2024-06-01to2025-05-31" id="Fact000036">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2024-06-01to2025-05-31" id="Fact000037">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2024-06-01to2025-05-31" id="Fact000038">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="From2024-06-01to2025-05-31" id="Fact000039">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2024-06-01to2025-05-31" id="Fact000040">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2024-06-01to2025-05-31" id="Fact000041">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="AsOf2024-11-30"
      decimals="-5"
      id="Fact000042"
      unitRef="USD">6400000</dei:EntityPublicFloat>
    <dei:EntityListingParValuePerShare
      contextRef="From2024-06-01to2025-05-31"
      decimals="INF"
      id="Fact000043"
      unitRef="USDPShares">0.08</dei:EntityListingParValuePerShare>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2025-09-26"
      decimals="INF"
      id="Fact000044"
      unitRef="Shares">2869900</dei:EntityCommonStockSharesOutstanding>
    <dei:AmendmentDescription contextRef="From2024-06-01to2025-05-31" id="Fact000047">This
Amendment No. 1 on Form 10-K/A (this &#x201c;Amendment No. 1&#x201d;) amends the Annual Report on Form 10-K for the fiscal year ended May
31, 2025 (the &#x201c;2025 Annual Report&#x201d;), originally filed by Biomerica, Inc. with the Securities and Exchange Commission (the
&#x201c;SEC&#x201d;) on August 29, 2025. References throughout this Amendment No. 1 to &#x201c;Biomerica, Inc.&#x201d;, &#x201c;Biomerica&#x201d;,
&#x201c;we&#x201d;, &#x201c;us&#x201d;, &#x201c;our&#x201d;, or the &#x201c;Company&#x201d; refer to Biomerica, Inc. and its subsidiaries, taken
as a whole, unless the context otherwise indicates.&#160;We
are filing this Amendment No. 1 pursuant to General Instruction G(3) of Form 10-K, as we do not intend to file a definitive proxy statement
for our 2025 Annual Meeting of stockholders (the &#x201c;Annual Meeting&#x201d;) within 120 days of the end of our fiscal year ended May
31, 2025. Accordingly, this Amendment No. 1 is being filed solely to:

&#160;



    &#160;
    &#x25cf;
    amend
    and restate Part III, Items 10 (Directors, Executive Officers and Corporate Governance), 11 (Executive Compensation), 12 (Security
    Ownership of Certain Beneficial Owners and Management Related Stockholder Matters), 13 (Certain Relationships and Related Transactions,
    and Director Independence) and 14 (Principal Accountant Fees and Services) of our 2025 Annual Report, in their entirety as set forth
    herein; and

    &#160;
    &#160;
    &#160;

    &#160;
    &#x25cf;
    file
    new certifications of our principal executive officer and principal financial officer as exhibits to this Amendment No. 1 under Item
    15 of Part IV hereof pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;).

&#160;

Because
no financial statements have been included in this Amendment No. 1, and because this Amendment No. 1 does not contain or amend any disclosure
with respect to paragraphs 3, 4 and 5 of Items 307 and 308 of Regulation S-K, the corresponding certifications have been omitted. We
are not including the certifications under Section 906 of the Sarbanes-Oxley Act of 2002, as no financial statements are being filed
with this Amendment No. 1.

&#160;

Except
as set forth above, no other Items of our 2025 Annual Report have been amended or revised in this Amendment No. 1, and all such other
Items shall be as set forth in such 2025 Annual Report. Accordingly, this Amendment No. 1 should be read in conjunction with the 2025
Annual Report and our other filings with the SEC. Certain capitalized terms used and not otherwise defined in this Amendment No. 1 have
the meanings given to them in the 2025 Annual Report.

&#160;

</dei:AmendmentDescription>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
